{ "version": "2.2", "instance": { "inpha-20260630.htm inpha-20260630_d2.htm": { "nsprefix": "inpha", "nsuri": "http://www.innate-pharma.com/20260630", "dts": { "inline": { "local": [ "inpha-20260630.htm", "inpha-20260630_d2.htm" ] }, "schema": { "local": [ "inpha-20260630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd" ] }, "calculationLink": { "local": [ "inpha-20260630_cal.xml" ] }, "definitionLink": { "local": [ "inpha-20260630_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "inpha-20260630_lab.xml" ] }, "presentationLink": { "local": [ "inpha-20260630_pre.xml" ] } }, "keyStandard": 202, "keyCustom": 131, "axisStandard": 26, "axisCustom": 1, "memberStandard": 34, "memberCustom": 116, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2025": 6 }, "contextCount": 541, "entityCount": 1, "segmentCount": 155, "elementCount": 616, "unitCount": 15, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 1244, "http://xbrl.sec.gov/dei/2025": 8 }, "report": { "R1": { "role": "http://www.innate-pharma.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition", "longName": "9952151 - Statement - Interim Condensed Consolidated Statements of Financial Position", "shortName": "Interim Condensed Consolidated Statements of Financial Position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:CurrentAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R3": { "role": "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss", "longName": "9952152 - Statement - Interim Condensed Consolidated Statements of Income (Loss)", "shortName": "Interim Condensed Consolidated Statements of Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R4": { "role": "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss", "longName": "9952153 - Statement - Interim Condensed Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Interim Condensed Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherComprehensiveIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R5": { "role": "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows", "longName": "9952154 - Statement - Interim Condensed Consolidated Statements of Cash Flows", "shortName": "Interim Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R6": { "role": "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlowsParenthetical", "longName": "9952155 - Statement - Interim Condensed Consolidated Statements of Cash Flows (Parenthetical)", "shortName": "Interim Condensed Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestPaidClassifiedAsOperatingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "link:footnote", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestPaidClassifiedAsOperatingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "link:footnote", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity", "longName": "9952156 - Statement - Interim Consolidated Statement of Changes in Shareholders\u2019 Equity", "shortName": "Interim Consolidated Statement of Changes in Shareholders\u2019 Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-8", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R8": { "role": "http://www.innate-pharma.com/role/TheCompanyandkeyevents", "longName": "9952157 - Disclosure - The Company and key events", "shortName": "The Company and key events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.innate-pharma.com/role/Basisofpresentationandstatementofcompliance", "longName": "9952158 - Disclosure - Basis of presentation and statement of compliance", "shortName": "Basis of presentation and statement of compliance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.innate-pharma.com/role/Managementoffinancialrisks", "longName": "9952159 - Disclosure - Management of financial risks", "shortName": "Management of financial risks", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.innate-pharma.com/role/Cashcashequivalentsshortterminvestmentsandnoncurrentfinancialassets", "longName": "9952160 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets", "shortName": "Cash, cash equivalents, short-term investments and non-current financial assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.innate-pharma.com/role/Tradereceivablesandothers", "longName": "9952161 - Disclosure - Trade receivables and others", "shortName": "Trade receivables and others", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.innate-pharma.com/role/Intangibleassets", "longName": "9952162 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.innate-pharma.com/role/Propertyandequipment", "longName": "9952163 - Disclosure - Property and equipment", "shortName": "Property and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.innate-pharma.com/role/Tradepayablesandothers", "longName": "9952164 - Disclosure - Trade payables and others", "shortName": "Trade payables and others", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.innate-pharma.com/role/Financialliabilities", "longName": "9952165 - Disclosure - Financial liabilities", "shortName": "Financial liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.innate-pharma.com/role/Employeebenefit", "longName": "9952166 - Disclosure - Employee benefit", "shortName": "Employee benefit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.innate-pharma.com/role/Capital", "longName": "9952167 - Disclosure - Capital", "shortName": "Capital", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.innate-pharma.com/role/Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement", "longName": "9952168 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement", "shortName": "Financial instruments recognized in the statement of financial position and related effect on the income statement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.innate-pharma.com/role/Revenueandotherincome", "longName": "9952169 - Disclosure - Revenue and other income", "shortName": "Revenue and other income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.innate-pharma.com/role/Operatingexpenses", "longName": "9952170 - Disclosure - Operating expenses", "shortName": "Operating expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.innate-pharma.com/role/Netfinancialincomeloss", "longName": "9952171 - Disclosure - Net financial income / (loss)", "shortName": "Net financial income / (loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.innate-pharma.com/role/Incometaxexpense", "longName": "9952172 - Disclosure - Income tax / (expense)", "shortName": "Income tax / (expense)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.innate-pharma.com/role/Commitmentscontingenciesandlitigation", "longName": "9952173 - Disclosure - Commitments, contingencies and litigation", "shortName": "Commitments, contingencies and litigation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.innate-pharma.com/role/Relatedpartytransactions", "longName": "9952174 - Disclosure - Related party transactions", "shortName": "Related party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.innate-pharma.com/role/Incomelosspershare", "longName": "9952175 - Disclosure - Income / (loss) per share", "shortName": "Income / (loss) per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.innate-pharma.com/role/Eventsafterthereportingdate", "longName": "9952176 - Disclosure - Events after the reporting date", "shortName": "Events after the reporting date", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies", "longName": "9955511 - Disclosure - Basis of presentation and statement of compliance (Policies)", "shortName": "Basis of presentation and statement of compliance (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceTables", "longName": "9955512 - Disclosure - Basis of presentation and statement of compliance (Tables)", "shortName": "Basis of presentation and statement of compliance (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables", "longName": "9955513 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets (Tables)", "shortName": "Cash, cash equivalents, short-term investments and non-current financial assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.innate-pharma.com/role/TradereceivablesandothersTables", "longName": "9955514 - Disclosure - Trade receivables and others (Tables)", "shortName": "Trade receivables and others (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.innate-pharma.com/role/PropertyandequipmentTables", "longName": "9955515 - Disclosure - Property and equipment (Tables)", "shortName": "Property and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.innate-pharma.com/role/TradepayablesandothersTables", "longName": "9955516 - Disclosure - Trade payables and others (Tables)", "shortName": "Trade payables and others (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfTradePayablesAndOthersTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfTradePayablesAndOthersTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.innate-pharma.com/role/FinancialliabilitiesTables", "longName": "9955517 - Disclosure - Financial liabilities (Tables)", "shortName": "Financial liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.innate-pharma.com/role/EmployeebenefitTables", "longName": "9955518 - Disclosure - Employee benefit (Tables)", "shortName": "Employee benefit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.innate-pharma.com/role/CapitalTables", "longName": "9955519 - Disclosure - Capital (Tables)", "shortName": "Capital (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables", "longName": "9955520 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)", "shortName": "Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.innate-pharma.com/role/RevenueandotherincomeTables", "longName": "9955521 - Disclosure - Revenue and other income (Tables)", "shortName": "Revenue and other income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.innate-pharma.com/role/OperatingexpensesTables", "longName": "9955522 - Disclosure - Operating expenses (Tables)", "shortName": "Operating expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.innate-pharma.com/role/NetfinancialincomelossTables", "longName": "9955523 - Disclosure - Net financial income / (loss) (Tables)", "shortName": "Net financial income / (loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.innate-pharma.com/role/IncometaxexpenseTables", "longName": "9955524 - Disclosure - Income tax / (expense) (Tables)", "shortName": "Income tax / (expense) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsTables", "longName": "9955525 - Disclosure - Related party transactions (Tables)", "shortName": "Related party transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.innate-pharma.com/role/IncomelosspershareTables", "longName": "9955526 - Disclosure - Income / (loss) per share (Tables)", "shortName": "Income / (loss) per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails", "longName": "9955527 - Disclosure - The Company and key events - The company (Details)", "shortName": "The Company and key events - The company (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "inpha:NumberOfWhollyOwnedSubsidiaries", "unitRef": "subsidiary", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R45": { "role": "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails", "longName": "9955528 - Disclosure - Basis of presentation and statement of compliance (Details)", "shortName": "Basis of presentation and statement of compliance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-51", "name": "inpha:UpfrontPaymentCommitment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-52", "name": "ifrs-full:ProceedsFromIssueOfOrdinaryShares", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R46": { "role": "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails", "longName": "9955529 - Disclosure - Basis of presentation and statement of compliance - Disclosure of effect of changes in foreign exchange rates (Details)", "shortName": "Basis of presentation and statement of compliance - Disclosure of effect of changes in foreign exchange rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails", "longName": "9955530 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of cash, cash equivalents and financial assets (Details)", "shortName": "Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of cash, cash equivalents and financial assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "inpha:CashCashEquivalentsAndShortTermInvestmentsAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R48": { "role": "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails", "longName": "9955531 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Additional information (Details)", "shortName": "Cash, cash equivalents, short-term investments and non-current financial assets - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-2", "name": "inpha:NumberOfMutualFundsInWhichTheEntityIsHoldingShares", "unitRef": "mutual_fund", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "inpha:NumberOfMutualFundsInWhichTheEntityIsHoldingShares", "unitRef": "mutual_fund", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails", "longName": "9955532 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of reconciliation of changes in short-term investments and non-current financial assets (Details)", "shortName": "Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of reconciliation of changes in short-term investments and non-current financial assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentInvestments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentInvestments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.innate-pharma.com/role/TradereceivablesandothersDetails", "longName": "9955533 - Disclosure - Trade receivables and others (Details)", "shortName": "Trade receivables and others (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:OtherCurrentReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:OtherCurrentReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails", "longName": "9955534 - Disclosure - Intangible assets - Additional information (Details)", "shortName": "Intangible assets - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "true", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-62", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ifrs-full:IntangibleAssetsOtherThanGoodwill", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R52": { "role": "http://www.innate-pharma.com/role/PropertyandequipmentDetails", "longName": "9955535 - Disclosure - Property and equipment (Details)", "shortName": "Property and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R53": { "role": "http://www.innate-pharma.com/role/TradepayablesandothersDetails", "longName": "9955536 - Disclosure - Trade payables and others (Details)", "shortName": "Trade payables and others (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfTradePayablesAndOthersTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfTradePayablesAndOthersTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "longName": "9955537 - Disclosure - Financial liabilities - Disclosure of financial liabilities per maturity (Details)", "shortName": "Financial liabilities - Disclosure of financial liabilities per maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:FinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R55": { "role": "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails", "longName": "9955538 - Disclosure - Financial liabilities - Additional Information (Details)", "shortName": "Financial liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": [ "span", "div", "ix:continuation", "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": [ "span", "div", "ix:continuation", "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails", "longName": "9955539 - Disclosure - Financial liabilities - Disclosure of maturity analysis for non-derivative financial liabilities (Details)", "shortName": "Financial liabilities - Disclosure of maturity analysis for non-derivative financial liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:BankBorrowingsUndiscountedCashFlows", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:BankBorrowingsUndiscountedCashFlows", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails", "longName": "9955540 - Disclosure - Employee benefit - Disclosure of defined benefit plans (Details)", "shortName": "Employee benefit - Disclosure of defined benefit plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails", "longName": "9955541 - Disclosure - Employee benefit - Disclosure of net defined benefit liability (asset) (Details)", "shortName": "Employee benefit - Disclosure of net defined benefit liability (asset) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R59": { "role": "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails", "longName": "9955542 - Disclosure - Employee benefit - Additional information (Details)", "shortName": "Employee benefit - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:RecognisedAssetsDefinedBenefitPlan", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:RecognisedAssetsDefinedBenefitPlan", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails", "longName": "9955543 - Disclosure - Capital - Additional Information (Details)", "shortName": "Capital - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R61": { "role": "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails", "longName": "9955544 - Disclosure - Capital - Disclosure of number and weighted average exercise prices of other equity instruments (Details)", "shortName": "Capital - Disclosure of number and weighted average exercise prices of other equity instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "share", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-382", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R62": { "role": "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails", "longName": "9955545 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement - Disclosure of detailed information about financial instruments (Details)", "shortName": "Financial instruments recognized in the statement of financial position and related effect on the income statement - Disclosure of detailed information about financial instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:FinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "ifrs-full:FinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails", "longName": "9955546 - Disclosure - Revenue and other income - Disclosure of revenue from collaboration and licensing agreements (Details)", "shortName": "Revenue and other income - Disclosure of revenue from collaboration and licensing agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-434", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R64": { "role": "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails", "longName": "9955547 - Disclosure - Revenue and other income - Additional information (Details)", "shortName": "Revenue and other income - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-465", "name": "inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R65": { "role": "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails", "longName": "9955548 - Disclosure - Revenue and other income - Disclosure of change in deferred revenue and collaboration liabilities (Details)", "shortName": "Revenue and other income - Disclosure of change in deferred revenue and collaboration liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "inpha:ForeignExchangeGainLossCurrentContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:ForeignExchangeGainLossCurrentContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails", "longName": "9955549 - Disclosure - Revenue and other income - Disclosure of variance of deferred revenue (Details)", "shortName": "Revenue and other income - Disclosure of variance of deferred revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-483", "name": "ifrs-full:ContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-484", "name": "inpha:IncreaseThroughUpfrontPaymentContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R67": { "role": "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails", "longName": "9955550 - Disclosure - Revenue and other income - Disclosure of government financing for research expenditures (Details)", "shortName": "Revenue and other income - Disclosure of government financing for research expenditures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "inpha:IncomeFromResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:IncomeFromResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails", "longName": "9955551 - Disclosure - Operating expenses - Disclosure of expenses by nature (Details)", "shortName": "Operating expenses - Disclosure of expenses by nature (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "inpha:SubcontractingCosts", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:SubcontractingCosts", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails", "longName": "9955552 - Disclosure - Operating expenses - Additional information (Details)", "shortName": "Operating expenses - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ShorttermEmployeeBenefitsExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-502", "name": "ifrs-full:NumberOfEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R70": { "role": "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails", "longName": "9955553 - Disclosure - Net financial income / (loss) - Disclosure of net financial income (loss) (Details)", "shortName": "Net financial income / (loss) - Disclosure of net financial income (loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "inpha:InterestsAndGainsOnFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inpha:InterestsAndGainsOnFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.innate-pharma.com/role/IncometaxexpenseAdditionalinformationDetails", "longName": "9955554 - Disclosure - Income tax / (expense) - Additional information (Details)", "shortName": "Income tax / (expense) - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-2", "name": "inpha:UnusedTaxLossesWithNoExpirationDate", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "inpha:UnusedTaxLossesWithNoExpirationDate", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails", "longName": "9955555 - Disclosure - Income tax / (expense) - Disclosure of Deferred Assets and Liabilities (Details)", "shortName": "Income tax / (expense) - Disclosure of Deferred Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-2", "name": "inpha:DeferredTaxAssetsOffsetAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "inpha:DeferredTaxAssetsOffsetAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.innate-pharma.com/role/CommitmentsDetails", "longName": "9955556 - Disclosure - Commitments (Details)", "shortName": "Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-2", "name": "inpha:NonCancellableOffBalanceSheetPurchasedCommitments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "inpha:NonCancellableOffBalanceSheetPurchasedCommitments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.innate-pharma.com/role/ProvisionsDetails", "longName": "9955557 - Disclosure - Provisions (Details)", "shortName": "Provisions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-2", "name": "ifrs-full:Provisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ReversalOfProvisionsForCostOfRestructuring", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R75": { "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails", "longName": "9955558 - Disclosure - Related party transactions - Disclosure of key management personnel compensation (Details)", "shortName": "Related party transactions - Disclosure of key management personnel compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails", "longName": "9955559 - Disclosure - Related party transactions - Additional information (Details)", "shortName": "Related party transactions - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-6", "name": "inpha:ProvisionForExpensesWithRelatedParties", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "inpha:ProvisionForExpensesWithRelatedParties", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails", "longName": "9955560 - Disclosure - Related party transactions - Disclosure of transactions between related parties (Details)", "shortName": "Related party transactions - Disclosure of transactions between related parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-534", "name": "ifrs-full:CashAdvancesAndLoansFromRelatedParties", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-534", "name": "ifrs-full:CashAdvancesAndLoansFromRelatedParties", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails", "longName": "9955561 - Disclosure - Income / (loss) per share - Summary of income (loss) per share (Details)", "shortName": "Income / (loss) per share - Summary of income (loss) per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares", "unitRef": "shares", "xsiNil": "true", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R79": { "role": "http://www.innate-pharma.com/role/IncomelosspershareDilutedincomelosspershareDetails", "longName": "9955562 - Disclosure - Income / (loss) per share - Diluted income / (loss) per share (Details)", "shortName": "Income / (loss) per share - Diluted income / (loss) per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "share", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-539", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } }, "R80": { "role": "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails", "longName": "9955563 - Disclosure - Events after the reporting date (Details)", "shortName": "Events after the reporting date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:IssueOfEquity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-540", "name": "inpha:NearTermDevelopmentMilestonePaymentsEligible", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inpha-20260630_d2.htm", "unique": true } } }, "tag": { "inpha_A2015AstraZenecaMonalizumabAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "A2015AstraZenecaMonalizumabAgreementsMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2015 monalizumab agreement, with AstraZeneca", "label": "2015 AstraZeneca Monalizumab Agreements [Member]", "documentation": "This member stands for 2015 AstraZeneca monalizumab agreements." } } }, "auth_ref": [] }, "inpha_A2018AstraZenecaIPH5201AgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "A2018AstraZenecaIPH5201AgreementMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPH5201 agreement, with AstraZeneca", "label": "2018 AstraZeneca IPH5201 Agreement [Member]", "documentation": "This member stands for Agreement related to IPH5201 with AstraZeneca." } } }, "auth_ref": [] }, "inpha_AGA202501Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGA202501Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA 2025-01", "label": "AGA 2025-01 [Member]", "documentation": "AGA 2025-01" } } }, "auth_ref": [] }, "inpha_AGA202502Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGA202502Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA 2025-02", "label": "AGA 2025-02 [Member]", "documentation": "AGA 2025-02" } } }, "auth_ref": [] }, "inpha_AGABonus20181Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGABonus20181Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2018-1", "label": "AGA Bonus 2018-1 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGABonus20191Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGABonus20191Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2019-1", "label": "AGA Bonus 2019-1 [Member]", "documentation": "Related to AGA bonus 2019-1." } } }, "auth_ref": [] }, "inpha_AGABonus202012Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGABonus202012Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2020-1 & 2", "label": "AGA Bonus 2020-1 & 2 [Member]", "documentation": "AGA Bonus 2020-1 & 2" } } }, "auth_ref": [] }, "inpha_AGABonus20211Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGABonus20211Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2021-1", "label": "AGA Bonus 2021-1 [Member]", "documentation": "AGA Bonus 2021-1" } } }, "auth_ref": [] }, "inpha_AGABonus20221Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGABonus20221Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Bonus 2022-1", "label": "AGA Bonus 2022-1 [Member]", "documentation": "AGA Bonus 2022-1" } } }, "auth_ref": [] }, "inpha_AGAEmployees2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAEmployees2017Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Employees 2017", "label": "AGA Employees 2017 [Member]", "documentation": "This member stands for AGA Employees 2017." } } }, "auth_ref": [] }, "inpha_AGAEmployees2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAEmployees2018Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Employees 2018", "label": "AGA Employees 2018 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGAEmployees20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAEmployees20241Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA employees 2024-1", "label": "AGA Employees 2024-1 [Member]", "documentation": "AGA Employees 2024-1" } } }, "auth_ref": [] }, "inpha_AGAManagement20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAManagement20161Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Management 2016-1", "label": "AGA Management 2016-1 [Member]", "documentation": "This member stands for AGA Management 2016-1." } } }, "auth_ref": [] }, "inpha_AGAManagement20162Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAManagement20162Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Management 2016-2", "label": "AGA Management 2016-2 [Member]", "documentation": "This member stands for AGA Management 2016-2." } } }, "auth_ref": [] }, "inpha_AGAManagement20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAManagement20241Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Management 2024-1", "label": "AGA Management 2024-1 [Member]", "documentation": "AGA Management 2024-1" } } }, "auth_ref": [] }, "inpha_AGAManagement2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAManagement2025Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Management 2025", "label": "AGA Management 2025 [Member]", "documentation": "AGA Management 2025" } } }, "auth_ref": [] }, "inpha_AGANewMembers20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGANewMembers20171Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA New Members 2017-1", "label": "AGA New Members 2017-1 [Member]", "documentation": "This member stands for AGA New Members 2017-1." } } }, "auth_ref": [] }, "inpha_AGANewMembers20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGANewMembers20231Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA New members 2023-1", "label": "AGA New Members 2023-1 [Member]", "documentation": "AGA New Members 2023-1" } } }, "auth_ref": [] }, "inpha_AGANewMembers20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGANewMembers20241Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA New members 2024-1", "label": "AGA New Members 2024-1 [Member]", "documentation": "AGA New Members 2024-1" } } }, "auth_ref": [] }, "inpha_AGAP2019Employees2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAP2019Employees2019Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP 2019 Employees 2019", "label": "AGAP 2019 Employees 2019 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGAP2019Management2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAP2019Management2019Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP 2019 Management 2019", "label": "AGAP 2019 Management 2019 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGAPEmployees20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPEmployees20161Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employees 2016-1", "label": "AGAP Employees 2016-1 [Member]", "documentation": "This member stands for AGAP Employees 2016-1." } } }, "auth_ref": [] }, "inpha_AGAPEmployees20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPEmployees20171Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employees 2017-1", "label": "AGAP Employees 2017-1 [Member]", "documentation": "Related to a plan." } } }, "auth_ref": [] }, "inpha_AGAPEmployees20201Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPEmployees20201Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employees 2020-1", "label": "AGAP Employees 2020-1 [Member]", "documentation": "AGAP Employees 2020-1" } } }, "auth_ref": [] }, "inpha_AGAPEmployees20211Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPEmployees20211Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Employees 2021-1", "label": "AGAP Employees 2021-1 [Member]", "documentation": "AGAP Employees 2021-1" } } }, "auth_ref": [] }, "inpha_AGAPManagement20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPManagement20161Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Management 2016-1", "label": "AGAP Management 2016-1 [Member]", "documentation": "This member stands for AGAP Management 2016-1." } } }, "auth_ref": [] }, "inpha_AGAPManagement20162Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPManagement20162Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Management 2016-2", "label": "AGAP Management 2016-2 [Member]", "documentation": "This member stands for AGAP Management 2016-2." } } }, "auth_ref": [] }, "inpha_AGAPManagement20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPManagement20171Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Management 2017-1", "label": "AGAP Management 2017-1 [Member]", "documentation": "Related to a plan." } } }, "auth_ref": [] }, "inpha_AGAPManagement20201Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPManagement20201Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Management 2020-1", "label": "AGAP Management 2020-1 [Member]", "documentation": "AGAP Management 2020-1" } } }, "auth_ref": [] }, "inpha_AGAPManagement20211Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPManagement20211Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Management 2021-1", "label": "AGAP Management 2021-1 [Member]", "documentation": "AGAP Management 2021-1" } } }, "auth_ref": [] }, "inpha_AGAPPerfEmployees20181Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPPerfEmployees20181Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Perf Employees 2018-1", "label": "AGAP Perf Employees 2018-1 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_AGAPPerfManagement20181Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPPerfManagement20181Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGAP Perf Management 2018-1", "label": "AGAP Perf Management 2018-1 [Member]", "documentation": "This member stands for AGA Perf Management 2018-1." } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees20221Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPerfEmployees20221Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2022-1", "label": "AGA Perf Employees 2022-1 [Member]", "documentation": "AGA Perf Employees 2022-1" } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPerfEmployees20231Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2023-1", "label": "AGA Perf Employees 2023-1 [Member]", "documentation": "AGA Perf Employees 2023-1" } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPerfEmployees20241Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2024-1", "label": "AGA Perf Employees 2024-1 [Member]", "documentation": "AGA Perf Employees 2024-1" } } }, "auth_ref": [] }, "inpha_AGAPerfEmployees20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPerfEmployees20251Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Employees 2025-1", "label": "AGA Perf Employees 2025-1 [Member]", "documentation": "AGA Perf Employees 2025-1" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20221Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPerfManagement20221Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2022-1", "label": "AGA Perf Management 2022-1 [Member]", "documentation": "AGA Perf Management 2022-1" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPerfManagement20231Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2023-1", "label": "AGA Perf Management 2023-1 [Member]", "documentation": "AGA Perf Management 2023-1" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPerfManagement20241Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2024-1", "label": "AGA Perf Management 2024-1 [Member]", "documentation": "AGA Perf Management 2024-1" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20242Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPerfManagement20242Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2024-2", "label": "AGA Perf Management 2024-2 [Member]", "documentation": "AGA Perf Management 2024-2" } } }, "auth_ref": [] }, "inpha_AGAPerfManagement20252Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPerfManagement20252Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA Perf Management 2025-2", "label": "AGA Perf Management 2025-2 [Member]", "documentation": "AGA Perf Management 2025-2" } } }, "auth_ref": [] }, "inpha_AGAPlanEpargneEntreprise2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPlanEpargneEntreprise2022Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA \"Plan Epargne Entreprise\" 2022", "label": "AGA \"Plan Epargne Entreprise\" 2022 [Member]", "documentation": "AGA \"Plan Epargne Entreprise\" 2022" } } }, "auth_ref": [] }, "inpha_AGAPlanEpargneEntreprise2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPlanEpargneEntreprise2023Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA \"Plan Epargne Entreprise\" 2023", "label": "AGA \"Plan Epargne Entreprise\" 2023 [Member]", "documentation": "AGA \"Plan Epargne Entreprise\" 2023" } } }, "auth_ref": [] }, "inpha_AGAPlanEpargneEntreprise2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AGAPlanEpargneEntreprise2024Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA \"Plan Epargne Entreprise\" 2024", "label": "AGA \"Plan Epargne Entreprise\" 2024 [Member]", "documentation": "AGA \"Plan Epargne Entreprise\" 2024" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income", "label": "Accumulated other comprehensive income [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r292" ] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of discount rates", "label": "Actuarial assumption of discount rates" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r276" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Additions other than through business combinations, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment including right-of-use assets other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r274" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares, diluted (in shares)", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r30" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accrued interests on financial assets", "label": "Adjustments for decrease (increase) in accrued income including contract assets" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in accrued income including contract assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Accrued income including contract assets; Profit (loss)]" } } }, "auth_ref": [ "r283" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others - current and non-current portion (excluding receivables related to Property & equipment), variance", "label": "Adjustments for decrease (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization, net", "label": "Adjustments for depreciation and amortisation expense" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of financial assets", "label": "Adjustments for fair value losses (gains)" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Disposal of property and equipment (scrapping)", "label": "Adjustments for gain (loss) on disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]" } } }, "auth_ref": [ "r285" ] }, "inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AdjustmentsForIncreaseDecreaseInCollaborationLiabilities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration liabilities - current and non-current portion, variance", "label": "Adjustments For Increase (Decrease) In Collaboration Liabilities", "documentation": "Adjustments for increase (decrease) in collaboration liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue - current and non-current portion, variance", "label": "Adjustments for increase (decrease) in deferred income including contract liabilities" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r283" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits costs", "label": "Adjustments for increase (decrease) in employee benefit liabilities" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and others (excluding payables related to capital expenditures), variance", "label": "Adjustments for increase (decrease) in trade and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_AdjustmentsForProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForProvisions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in provision for charges", "label": "Adjustments for provisions" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Adjustments for share-based payments" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange (gains) losses on financial assets", "label": "Adjustments for unrealised foreign exchange losses (gains)" } } }, "auth_ref": [ "r242", "r284" ] }, "inpha_AdministrationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AdministrationMember", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Administration", "label": "Administration [Member]", "documentation": "Administration" } } }, "auth_ref": [] }, "inpha_AgreementRelatedToIPH6101WithSanofiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AgreementRelatedToIPH6101WithSanofiMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Agreement with Sanofi, 2016", "terseLabel": "Agreement with Sanofi, 2016", "label": "Agreement Related To IPH6101 With Sanofi [Member]", "documentation": "Agreement Related To IPH6101 With Sanofi" } } }, "auth_ref": [] }, "inpha_AgreementWithSanofi2022ANKETIPH62Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AgreementWithSanofi2022ANKETIPH62Member", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement with Sanofi, 2022 - ANKET IPH62", "label": "Agreement With Sanofi 2022 - ANKET IPH62 [Member]", "documentation": "Agreement With Sanofi 2022 - ANKET IPH62" } } }, "auth_ref": [] }, "inpha_AgreementWithSanofi2022ANKETIPH67Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AgreementWithSanofi2022ANKETIPH67Member", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement With Sanofi 2022 - ANKET IPH67", "label": "Agreement With Sanofi 2022 - ANKET IPH67 [Member]", "documentation": "Agreement With Sanofi 2022 - ANKET IPH67" } } }, "auth_ref": [] }, "inpha_AgreementsWithGenzymeForNKCellEngagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AgreementsWithGenzymeForNKCellEngagesMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements with Genzyme for NK Cell engages", "label": "Agreements with Genzyme for NK Cell engages [Member]", "documentation": "Agreements with Genzyme for NK Cell engages" } } }, "auth_ref": [] }, "inpha_AgreementsWithSanofiForNKCellEngagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AgreementsWithSanofiForNKCellEngagesMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements with Sanofi for NK Cell engages", "label": "Agreements with Sanofi for NK Cell engages [Member]", "documentation": "Agreements with Sanofi for NK Cell engages" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": { "parentTag": "inpha_NetAmountsReceivablePayableRelatedPartyTransactions", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails", "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts payable, related party transactions", "negatedLabel": "Liabilities", "label": "Amounts payable, related party transactions" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r21", "r24", "r154" ] }, "ifrs-full_AmountsReceivableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsReceivableRelatedPartyTransactions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": { "parentTag": "inpha_NetAmountsReceivablePayableRelatedPartyTransactions", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Receivables", "label": "Amounts receivable, related party transactions" } }, "en": { "role": { "documentation": "The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r21", "r24", "r154" ] }, "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AnalysisOfIncomeAndExpenseAbstract", "lang": { "en-us": { "role": { "terseLabel": "Analysis of income and expense [abstract]", "label": "Analysis of income and expense [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applicable tax rate", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r4", "r144" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r63", "r64", "r65", "r112", "r115", "r180", "r181", "r206" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "inpha_AstraZenecaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "AstraZenecaMember", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AstraZeneca", "label": "AstraZeneca [Member]", "documentation": "AstraZeneca" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [axis]", "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r290", "r293" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function", "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r290", "r293" ] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Average rate (\u20ac1 equals to USD)", "label": "Average foreign exchange rate" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r293" ] }, "inpha_BSA20112Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSA20112Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2011-2", "label": "BSA 2011-2 [Member]", "documentation": "Related to the plan." } } }, "auth_ref": [] }, "inpha_BSA2013Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSA2013Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2013", "label": "BSA 2013 [Member]", "documentation": "This member stands for BSA 2013." } } }, "auth_ref": [] }, "inpha_BSA2014Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSA2014Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2014", "label": "BSA 2014 [Member]", "documentation": "This member stands for BSA 2014." } } }, "auth_ref": [] }, "inpha_BSA20151Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSA20151Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2015-1", "label": "BSA 2015-1 [Member]", "documentation": "This member stands for BSA 2015-1." } } }, "auth_ref": [] }, "inpha_BSA20152Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSA20152Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2015-2", "label": "BSA 2015-2 [Member]", "documentation": "This member stands for BSA 2015-2." } } }, "auth_ref": [] }, "inpha_BSA2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSA2017Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2017", "label": "BSA 2017 [Member]", "documentation": "This member stands for BSA 2017." } } }, "auth_ref": [] }, "inpha_BSA20221Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSA20221Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2022-1", "label": "BSA 2022-1 [Member]", "documentation": "BSA 2022-1" } } }, "auth_ref": [] }, "inpha_BSA20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSA20231Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2023-1", "label": "BSA 2023-1 [Member]", "documentation": "BSA 2023-1" } } }, "auth_ref": [] }, "inpha_BSA20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSA20251Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA 2025-1", "label": "BSA 2025-1 [Member]", "documentation": "BSA 2025-1" } } }, "auth_ref": [] }, "inpha_BSAAR2011Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSAAR2011Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSAAR 2011", "label": "BSAAR 2011 [Member]", "documentation": "This member stands for BSAAR 2011." } } }, "auth_ref": [] }, "inpha_BSAAR2012Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSAAR2012Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSAAR 2012", "label": "BSAAR 2012 [Member]", "documentation": "This member stands for BSAAR 2012." } } }, "auth_ref": [] }, "inpha_BSAAR2015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BSAAR2015Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSAAR 2015", "label": "BSAAR 2015 [Member]", "documentation": "This member stands for BSAAR 2015." } } }, "auth_ref": [] }, "ifrs-full_BankBorrowingsUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BankBorrowingsUndiscountedCashFlows", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Undiscounted cash flows", "label": "Bank borrowings, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r253", "r257" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Basic income (loss) per share (in EUR per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r28", "r29" ] }, "inpha_BorrowingGracePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BorrowingGracePeriod", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, grace period", "label": "Borrowing, Grace Period", "documentation": "Borrowing, Grace Period" } } }, "auth_ref": [] }, "inpha_BorrowingMaturity": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BorrowingMaturity", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, maturity", "label": "Borrowing, Maturity", "documentation": "Borrowing, Maturity" } } }, "auth_ref": [] }, "inpha_BorrowingMaturityExtensionPeriodOption": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BorrowingMaturityExtensionPeriodOption", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, maturity, extension period option", "label": "Borrowing, Maturity, Extension Period Option", "documentation": "Borrowing, Maturity, Extension Period Option" } } }, "auth_ref": [] }, "inpha_BorrowingNumberOfLoanAgreement": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BorrowingNumberOfLoanAgreement", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/TradepayablesandothersDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, number of loan agreement", "label": "Borrowing, Number Of Loan Agreement", "documentation": "Borrowing, Number Of Loan Agreement" } } }, "auth_ref": [] }, "inpha_BorrowingPercentageOfStateGuaranteedLoan": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BorrowingPercentageOfStateGuaranteedLoan", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing, percentage of state-guaranteed loan", "label": "Borrowing, Percentage Of State-Guaranteed Loan", "documentation": "Borrowing, Percentage Of State-Guaranteed Loan" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/TradepayablesandothersDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [axis]", "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r288" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/TradepayablesandothersDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name", "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r288" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, interest rate", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r288" ] }, "inpha_BorrowingsMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "BorrowingsMaturityPeriod", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, maturity period", "label": "Borrowings, Maturity Period", "documentation": "Borrowings, Maturity Period" } } }, "auth_ref": [] }, "inpha_CapitalIncreaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CapitalIncreaseMember", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital increase", "label": "Capital Increase [Member]", "documentation": "Capital Increase" } } }, "auth_ref": [] }, "ifrs-full_CashAdvancesAndLoansFromRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAdvancesAndLoansFromRelatedParties", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": { "parentTag": "inpha_NetCashAdvanceReceivedFromMadeToRelatedParties", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Collection", "label": "Cash advances and loans from related parties" } }, "en": { "role": { "documentation": "The cash inflow from advances and loans from related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r282" ] }, "ifrs-full_CashAdvancesAndLoansMadeToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAdvancesAndLoansMadeToRelatedParties", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": { "parentTag": "inpha_NetCashAdvanceReceivedFromMadeToRelatedParties", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments", "label": "Cash advances and loans made to related parties" } }, "en": { "role": { "documentation": "The cash outflow for loans and advances made to related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r281" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails": { "parentTag": "inpha_CashCashEquivalentsAndShortTermInvestmentsAssets", "weight": 1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at the beginning of the year:", "periodEndLabel": "Cash and cash equivalents at the end of the six-months period:", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r45", "r59", "r138", "r202" ] }, "inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, and financial assets denominated in US dollars", "label": "Cash, Cash Equivalents, And Financial Assets Denominated In US Dollars [Member]", "documentation": "Related to cash, cash equivalents, and financial assets denominated in US dollars." } } }, "auth_ref": [] }, "inpha_CashCashEquivalentsAndShortTermInvestmentsAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CashCashEquivalentsAndShortTermInvestmentsAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails": { "parentTag": "inpha_TotalCashCashEquivalentsAndFinancialAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, cash equivalents and short-term investments", "label": "Cash, Cash Equivalents And Short-Term Investments, Assets", "documentation": "Cash, Cash Equivalents And Short-Term Investments, Assets" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash generated / (used in) from financing activities:", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r39", "r46" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash generated from / (used in) investing activities:", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r39", "r46" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash generated from / (used in) operating activities:", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r39", "r46" ] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Operating cash flow before change in working capital", "label": "Cash flows from (used in) operations before changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r242", "r285" ] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [axis]", "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r104", "r173" ] }, "ifrs-full_CategoriesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets", "label": "Categories of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r104", "r173" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities [axis]", "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r104", "r173" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities", "label": "Categories of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r104", "r173" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails", "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of related parties [axis]", "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r23", "r156" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails", "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of related parties", "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r23", "r156" ] }, "inpha_ChangeInValuationAllowanceOfFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ChangeInValuationAllowanceOfFinancialInstruments", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains on financial assets", "label": "Change In Valuation Allowance Of Financial Instruments", "documentation": "" } } }, "auth_ref": [] }, "inpha_ChangeInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ChangeInWorkingCapital", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total change in Working Capital", "label": "Change In Working Capital", "documentation": "The amount of working capital." } } }, "auth_ref": [] }, "ifrs-full_ChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInEquityAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in equity [abstract]", "label": "Changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CharacteristicsOfDefinedBenefitPlansAxis", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Characteristics of defined benefit plans [axis]", "label": "Characteristics of defined benefit plans [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r231" ] }, "ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CharacteristicsOfDefinedBenefitPlansDomain", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Characteristics of defined benefit plans", "label": "Characteristics of defined benefit plans [domain]" } }, "en": { "role": { "documentation": "This member stands for all defined benefit plans when disaggregated by characteristics of defined benefits plans. It also represents the standard value for the 'Characteristics of defined benefit plans' axis if no other member is used." } } }, "auth_ref": [ "r231" ] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails", "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets [axis]", "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r82", "r97", "r98", "r120", "r121", "r191" ] }, "ifrs-full_ClassesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsDomain", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails", "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets [domain]", "label": "Classes of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r82", "r97", "r98", "r120", "r121", "r191" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [axis]", "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r97", "r98", "r120", "r121" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [domain]", "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r97", "r98", "r120", "r121" ] }, "ifrs-full_ClassesOfLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesAxis", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of liabilities [axis]", "label": "Classes of liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r66", "r182" ] }, "ifrs-full_ClassesOfLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesDomain", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of liabilities [domain]", "label": "Classes of liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } } }, "auth_ref": [ "r66", "r182" ] }, "ifrs-full_ClassesOfOtherProvisionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfOtherProvisionsDomain", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of other provisions [domain]", "label": "Classes of other provisions [domain]" } }, "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } } }, "auth_ref": [ "r32", "r159" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [axis]", "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r8", "r147" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [domain]", "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r8", "r147" ] }, "ifrs-full_ClassesOfProvisionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfProvisionsAxis", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of other provisions [axis]", "label": "Classes of other provisions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r32", "r159" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [axis]", "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r136", "r186", "r219" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [domain]", "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r136", "r186", "r219" ] }, "inpha_ClinicalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ClinicalServicesMember", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Services", "label": "Clinical Services [Member]", "documentation": "Clinical Services" } } }, "auth_ref": [] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Closing rate (\u20ac1 equals to USD)", "label": "Closing foreign exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r293" ] }, "inpha_CollaborationAndLicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CollaborationAndLicensingAgreementsMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from collaboration and licensing agreements", "label": "Collaboration And Licensing Agreements [Member]", "documentation": "This member stands for collaboration and licensing agreements." } } }, "auth_ref": [] }, "inpha_CollaborationLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CollaborationLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "inpha_ChangeInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Collaboration liabilities - current and non-current portion", "label": "Collaboration Liabilities", "documentation": "The amount of collaboration liabilities." } } }, "auth_ref": [] }, "inpha_CollaborationLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CollaborationLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration liabilities \u2013 current portion", "label": "Collaboration Liabilities, Current", "documentation": "The amount of current collaboration liabilities." } } }, "auth_ref": [] }, "inpha_CollaborationLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CollaborationLiabilitiesMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration liabilities", "label": "Collaboration Liabilities [Member]", "documentation": "This member stands for collaboration liabilities." } } }, "auth_ref": [] }, "inpha_CollaborationLiabilitiesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CollaborationLiabilitiesNonCurrent", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration liabilities \u2013 non-current portion", "label": "Collaboration Liabilities, Non-current", "documentation": "The amount of non-current collaboration liabilities." } } }, "auth_ref": [] }, "inpha_CommitmentsContingenciesAndLitigationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CommitmentsContingenciesAndLitigationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments, Contingencies And Litigations [Abstract]", "label": "Commitments, Contingencies And Litigations [Abstract]", "documentation": "Commitments, Contingencies And Litigations" } } }, "auth_ref": [] }, "inpha_CompanyInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CompanyInformationAbstract", "lang": { "en-us": { "role": { "label": "Company Information [Abstract]", "documentation": "Company Information" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails", "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails", "http://www.innate-pharma.com/role/IncomelosspershareDilutedincomelosspershareDetails", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r197" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails", "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails", "http://www.innate-pharma.com/role/IncomelosspershareDilutedincomelosspershareDetails", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [domain]", "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r197" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Elements which will be reclassified in the consolidated statement of income (loss)", "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Items which will not reclassified in the consolidated statement of income (loss)", "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income (loss)", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r49", "r51", "r56", "r158", "r166", "r193", "r222", "r243" ] }, "ifrs-full_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In progress", "label": "Construction in progress [member]" } }, "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r273" ] }, "ifrs-full_ContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contract liabilities at beginning of period", "periodEndLabel": "Contract liabilities at end of period", "label": "Contract liabilities" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } } }, "auth_ref": [ "r68", "r71", "r124" ] }, "ifrs-full_ContractLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Contract liabilities [abstract]" } } }, "auth_ref": [] }, "inpha_ContractLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ContractLiabilitiesMember", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities / Deferred revenue", "label": "Contract Liabilities [Member]", "documentation": "Contract Liabilities" } } }, "auth_ref": [] }, "ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments (benefits and contributions paid by the employer)", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from resulting from contributions to plan by employer" } }, "en": { "role": { "documentation": "The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [domain]]" } } }, "auth_ref": [ "r14" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAdvancesToSuppliers", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepayments made to suppliers", "label": "Current advances to suppliers" } }, "en": { "role": { "documentation": "The amount of current advances made to suppliers before goods or services are received." } } }, "auth_ref": [ "r293" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r52", "r210", "r243" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current borrowings and current portion of non-current borrowings", "label": "Current borrowings and current portion of non-current borrowings" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Current contract liabilities at the beginning of period", "periodEndLabel": "Current contract liabilities at end of period", "label": "Current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r68" ] }, "ifrs-full_CurrentContractLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentContractLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current contract liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDeferredIncomeIncludingCurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue \u2013 current portion", "label": "Current deferred income including current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r296", "r299" ] }, "ifrs-full_CurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails": { "parentTag": "inpha_CashCashEquivalentsAndShortTermInvestmentsAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "verboseLabel": "Short-term investments", "label": "Current financial assets" } }, "en": { "role": { "documentation": "The amount of current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r89" ] }, "ifrs-full_CurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities \u2013 current portion", "label": "Current financial liabilities" } }, "en": { "role": { "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r89" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentInvestments", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, current investments", "periodEndLabel": "Ending balance, current investments", "label": "Current investments" } }, "en": { "role": { "documentation": "The amount of current investments." } } }, "auth_ref": [ "r296" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r54", "r211", "r243" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "inpha_CurrentPayablesRelatedToCapitalExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CurrentPayablesRelatedToCapitalExpenditures", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payables related to capital expenditures", "label": "Current Payables Related To Capital Expenditures", "documentation": "The amount of current payables related to capital expenditures." } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses", "terseLabel": "Current prepaid expenses", "label": "Current prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r293" ] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions - current portion", "label": "Current provisions" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r204" ] }, "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Service cost", "label": "Increase in net defined benefit liability (asset) resulting from current service cost" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r12", "r150" ] }, "ifrs-full_CurrentTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncome", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current tax expense (income)", "label": "Current tax expense (income)" } } }, "auth_ref": [ "r229", "r262" ] }, "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Trade payables and others (excluding payables related to capital expenditures)", "label": "Current Trade Payables And Others Excluding Payables Related To Capital Expenditures", "documentation": "The amount of current Trade payables and others, excluding payables related to capital expenditures." } } }, "auth_ref": [] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade account receivables", "label": "Current trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r263", "r267", "r269" ] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "VAT refund", "label": "Current value added tax receivables" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r297" ] }, "inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DecreaseThroughDerecognitionNonCurrentFinancialAssets", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": "inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-current financial assets, disposals", "label": "Decrease Through Derecognition Non-current Financial Assets", "documentation": "The decrease in non-current financial assets resulting from derecognition." } } }, "auth_ref": [] }, "inpha_DecreaseThroughDerecognitionShortTermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DecreaseThroughDerecognitionShortTermInvestment", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": "inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Short-term investments, disposals", "label": "Decrease Through Derecognition Short-term Investment", "documentation": "The decrease in current investment resulting from derecognition." } } }, "auth_ref": [] }, "inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total, disposals", "label": "Decrease Through Derecognition Short-term Investment And Non-current Financial Assets", "documentation": "The decrease in short-term investment and non-current financial assets resulting from derecognition." } } }, "auth_ref": [] }, "ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Revenue for the six months period", "negatedTerseLabel": "Recognition in P&L", "label": "Decrease through performance obligation being satisfied, contract liabilities" } }, "en": { "role": { "documentation": "The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [domain]]" } } }, "auth_ref": [ "r246" ] }, "inpha_DecreaseThroughPerformanceObligationBeingSatisfiedCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedCurrentContractLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Revenue for the six months period", "label": "Decrease Through Performance Obligation Being Satisfied, Current Contract Liabilities", "documentation": "Decrease Through Performance Obligation Being Satisfied, Current Contract Liabilities" } } }, "auth_ref": [] }, "inpha_DecreaseThroughPerformanceObligationBeingSatisfiedNonCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedNonCurrentContractLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Revenue for the six months period", "label": "Decrease Through Performance Obligation Being Satisfied, Non Current Contract Liabilities", "documentation": "Decrease Through Performance Obligation Being Satisfied, Non Current Contract Liabilities" } } }, "auth_ref": [] }, "inpha_DecreaseThroughRepaymentsContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DecreaseThroughRepaymentsContractLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deductions", "label": "Decrease Through Repayments, Contract Liabilities", "documentation": "The decrease in contract liabilities resulting from deductions." } } }, "auth_ref": [] }, "inpha_DecreaseThroughRepaymentsCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DecreaseThroughRepaymentsCurrentContractLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deductions", "label": "Decrease Through Repayments, Current Contract Liabilities", "documentation": "Decrease Through Repayments, Current Contract Liabilities" } } }, "auth_ref": [] }, "inpha_DecreaseThroughRepaymentsNonCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DecreaseThroughRepaymentsNonCurrentContractLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deductions", "label": "Decrease Through Repayments, Non Current Contract Liabilities", "documentation": "Decrease Through Repayments, Non Current Contract Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DeferredIncomeIncludingContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredIncomeIncludingContractLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "inpha_ChangeInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred revenue - current and non-current portion", "label": "Deferred income including contract liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r296", "r299" ] }, "inpha_DeferredRevenueAndCollaborationLiabilitiesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DeferredRevenueAndCollaborationLiabilitiesRollForward", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue And Collaboration Liabilities [Roll Forward]", "label": "Deferred Revenue And Collaboration Liabilities [Roll Forward]", "documentation": "Deferred Revenue And Collaboration Liabilities" } } }, "auth_ref": [] }, "inpha_DeferredRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DeferredRevenueMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities / Deferred revenue", "label": "Deferred Revenue [Member]", "documentation": "This member stands for deferred revenue." } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset", "label": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r5", "r145", "r205", "r207" ] }, "inpha_DeferredTaxAssetsOffsetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DeferredTaxAssetsOffsetAmount", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax assets", "label": "Deferred Tax Assets, Offset Amount", "documentation": "Deferred Tax Assets, Offset Amount" } } }, "auth_ref": [] }, "inpha_DeferredTaxLiabilitiesOffsetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DeferredTaxLiabilitiesOffsetAmount", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax liabilities", "label": "Deferred Tax Liabilities, Offset Amount", "documentation": "Deferred Tax Liabilities, Offset Amount" } } }, "auth_ref": [] }, "ifrs-full_DefinedBenefitObligationAtPresentValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DefinedBenefitObligationAtPresentValue", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Defined benefit obligations", "label": "Defined benefit obligation, at present value" } }, "en": { "role": { "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]" } } }, "auth_ref": [ "r277" ] }, "ifrs-full_DepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation and amortization", "label": "Depreciation and amortisation expense" } }, "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } } }, "auth_ref": [ "r60", "r110", "r116", "r192", "r228", "r265" ] }, "ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails", "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation", "terseLabel": "Depreciation", "label": "Depreciation, property, plant and equipment including right-of-use assets" } } }, "auth_ref": [ "r274" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Translation of transactions denominated in foreign currency", "label": "Description of accounting policy for foreign currency translation [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r294" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently issued accounting standards and interpretations", "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]" } } }, "auth_ref": [ "r47", "r140" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted income (loss) per share (in EUR per share)", "verboseLabel": "Diluted income/(loss) per share (in EUR per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r28", "r29" ] }, "ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustment for share instruments (in shares)", "label": "Dilutive effect of convertible instruments on weighted average number of ordinary shares" } }, "en": { "role": { "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed conversion of the entity's convertible instruments." } } }, "auth_ref": [ "r279" ] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of judgments and estimates", "label": "Disclosure of accounting judgements and estimates [text block]" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of preparation", "label": "Disclosure of basis of preparation of financial statements [text block]" } } }, "auth_ref": [ "r289" ] }, "inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of cash, cash equivalents and financial assets", "label": "Disclosure Of Cash, Cash Equivalents And Financial Assets [Text Block]", "documentation": "The disclosure of cash, cash equivalents and financial assets." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of changes in the share capital", "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [Table]", "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r136", "r186", "r219" ] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Commitmentscontingenciesandlitigation" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments, contingencies and litigation", "label": "Disclosure of commitments and contingent liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r289" ] }, "inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock", "presentation": [ "http://www.innate-pharma.com/role/TheCompanyandkeyevents" ], "lang": { "en-us": { "role": { "terseLabel": "The Company and key events", "label": "Disclosure Of Company, Significant Agreements And Key Events [Text Block]", "documentation": "Disclosure Of Company, Significant Agreements And Key Events" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesLineItems", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [table]", "label": "Disclosure of contingent liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesTable", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [table]", "label": "Disclosure of contingent liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } } }, "auth_ref": [ "r34", "r161" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansExplanatory", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans", "label": "Disclosure of defined benefit plans [text block]" } }, "en": { "role": { "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r10", "r148" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansLineItems", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails", "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [line items]", "label": "Disclosure of defined benefit plans [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails", "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [table]", "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r10", "r148" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments", "label": "Disclosure of detailed information about financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r90", "r93", "r99", "r168" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment", "label": "Disclosure of detailed information about property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r8", "r147" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of revenue from collaboration and licensing agreements", "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]" } } }, "auth_ref": [ "r70", "r123" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]", "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r70", "r123" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Incomelosspershare" ], "lang": { "en-us": { "role": { "terseLabel": "Income / (loss) per share", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r31" ] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of effect of changes in foreign exchange rates", "label": "Disclosure of effect of changes in foreign exchange rates [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r17" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Employeebenefit" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefit", "label": "Disclosure of employee benefits [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r15" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Eventsafterthereportingdate" ], "lang": { "en-us": { "role": { "terseLabel": "Events after the reporting date", "label": "Disclosure of events after reporting period [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r1" ] }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesByNatureExplanatory", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of expenses by nature", "label": "Disclosure of expenses by nature [text block]" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_DisclosureOfExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Operatingexpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Disclosure of expenses [text block]" } }, "en": { "role": { "documentation": "The disclosure of expenses." } } }, "auth_ref": [ "r289" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Netfinancialincomeloss" ], "lang": { "en-us": { "role": { "terseLabel": "Net financial income / (loss)", "label": "Disclosure of finance income (cost) [text block]" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Cashcashequivalentsshortterminvestmentsandnoncurrentfinancialassets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, short-term investments and non-current financial assets", "label": "Disclosure of financial assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r99", "r168" ] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [Line Items]", "label": "Disclosure of financial assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [Table]", "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r99", "r168" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments recognized in the statement of financial position and related effect on the income statement", "label": "Disclosure of financial instruments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [line items]", "label": "Disclosure of detailed information about financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [table]", "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r90", "r93", "r99", "r168" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Financialliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Disclosure of financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r99", "r168" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesLineItems", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [Line Items]", "label": "Disclosure of financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities per maturity", "label": "Disclosure Of Financial Liabilities Per Maturity [Table Text Block]", "documentation": "The disclosure of financial liabilities per maturity." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesTable", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [Table]", "label": "Disclosure of financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } } }, "auth_ref": [ "r99", "r168" ] }, "inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of government financing for research expenditures", "label": "Disclosure Of Government Financing For Research Expenditures [Table Text Block]", "documentation": "The disclosure of government financing for research expenditures." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Incometaxexpense" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax / (expense)", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r7" ] }, "inpha_DisclosureOfIncomeTaxLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfIncomeTaxLineItems", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseAdditionalinformationDetails", "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Income Tax [Line Items]", "label": "Disclosure Of Income Tax [Line Items]", "documentation": "Disclosure Of Income Tax [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutDefinedBenefitPlansAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of information about defined benefit plans [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Intangibleassets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Disclosure of intangible assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r38" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [line items]", "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [table]", "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r36", "r163" ] }, "ifrs-full_DisclosureOfIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIssuedCapitalExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Capital" ], "lang": { "en-us": { "role": { "terseLabel": "Capital", "label": "Disclosure of issued capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r289" ] }, "inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfKeyManagementPersonnelCompensationTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of key management personnel compensation", "label": "Disclosure Of Key Management Personnel Compensation [Table Text Block]", "documentation": "The disclosure for key management personnel compensation." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Basisofpresentationandstatementofcompliance" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation and statement of compliance", "label": "Disclosure of material accounting policy information [text block]" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r139", "r187", "r198" ] }, "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement Line Items [Line Items]", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement Table [Table]", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities." } } }, "auth_ref": [ "r95", "r179" ] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Managementoffinancialrisks" ], "lang": { "en-us": { "role": { "terseLabel": "Management of financial risks", "label": "Disclosure of nature and extent of risks arising from financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of information that enables users of financial statements to evaluate the nature and extent of risks arising from financial instruments to which the entity is exposed. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r90" ] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of net defined benefit liability (asset)", "label": "Disclosure of net defined benefit liability (asset) [text block]" } }, "en": { "role": { "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r11", "r149" ] }, "inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfNetFinancialIncomeLossTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of net financial income (loss)", "label": "Disclosure Of Net Financial Income (Loss) [Table Text Block]", "documentation": "The disclosure of net financial income (loss)." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-adjusting events after reporting period [abstract]", "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]", "label": "Disclosure of non-adjusting events after reporting period [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-adjusting events after reporting period [table]", "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r0", "r141" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/CapitalTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of number and weighted average exercise prices of other equity instruments", "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r286" ] }, "inpha_DisclosureOfOperatingExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfOperatingExpensesLineItems", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of operating expenses [Line Items]", "label": "Disclosure of operating expenses [Line Items]", "documentation": "Disclosure of operating expenses [Line Items]" } } }, "auth_ref": [] }, "inpha_DisclosureOfOperatingExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfOperatingExpensesTable", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of operating expenses [Table]", "label": "Disclosure of operating expenses [Table]", "documentation": "Disclosure of operating expenses [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsLineItems", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement Line Items [Line Items]", "label": "Disclosure of operating segments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsTable", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of operating segments [Table]", "label": "Disclosure of operating segments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } } }, "auth_ref": [ "r112" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Propertyandequipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Disclosure of property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r9" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [Line Items]", "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]", "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r8", "r147" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of changes in short-term investments and non-current financial assets", "label": "Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in the loss allowance and explanation of changes in the gross carrying amount for financial instruments. Loss allowance is the allowance for expected credit losses on financial assets measured in accordance with paragraph 4.1.2 of IFRS 9, lease receivables and contract assets, the accumulated impairment amount for financial assets measured in accordance with paragraph 4.1.2A of IFRS 9 and the provision for expected credit losses on loan commitments and financial guarantee contracts. [Refer: Gross carrying amount [member]]" } } }, "auth_ref": [ "r91", "r92", "r176", "r177" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Relatedpartytransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transactions", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r25" ] }, "ifrs-full_DisclosureOfRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRevenueExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Revenueandotherincome" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue and other income", "label": "Disclosure of revenue [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for revenue." } } }, "auth_ref": [ "r289" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]" } }, "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } } }, "auth_ref": [ "r6", "r146" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseAdditionalinformationDetails", "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r6", "r146" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [Line Items]", "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [Table]", "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r84", "r167" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Tradepayablesandothers" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and others", "label": "Disclosure of trade and other payables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/Tradereceivablesandothers" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others", "label": "Disclosure of trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r289" ] }, "inpha_DisclosureOfTradePayablesAndOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfTradePayablesAndOthersLineItems", "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of trade payables and others [Line Items]", "label": "Disclosure of trade payables and others [Line Items]", "documentation": "Disclosure of trade payables and others [Line Items]" } } }, "auth_ref": [] }, "inpha_DisclosureOfTradePayablesAndOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfTradePayablesAndOthersTable", "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of trade payables and others [Table]", "label": "Disclosure of trade payables and others [Table]", "documentation": "Disclosure of trade payables and others [Table]" } } }, "auth_ref": [] }, "inpha_DisclosureOfTradePayablesAndOthersTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfTradePayablesAndOthersTextBlock", "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of trade payables and others", "label": "Disclosure Of Trade Payables And Others [Text Block]", "documentation": "The disclosure of trade payables and others." } } }, "auth_ref": [] }, "inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfTradeReceivablesAndOtherTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of trade receivables and others", "label": "Disclosure Of Trade Receivables And Other [Table Text Block]", "documentation": "The disclosure of trade receivables and other." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties", "label": "Disclosure of transactions between related parties [text block]" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r22", "r155" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails", "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [Line Items]", "label": "Disclosure of transactions between related parties [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails", "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [Table]", "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r23", "r156" ] }, "inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisclosureOfVarianceOfDeferredRevenueTableTextBlock", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of variance of deferred revenue", "label": "Disclosure Of Variance Of Deferred Revenue [Table Text Block]", "documentation": "The disclosure of variance of deferred revenue." } } }, "auth_ref": [] }, "inpha_DisposalOfCurrentFinancialInstrumentsAndPaidInterestsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "DisposalOfCurrentFinancialInstrumentsAndPaidInterestsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal of current financial instruments and paid interests", "label": "Disposal Of Current Financial Instruments And Paid Interests, Classified As Investing Activities", "documentation": "Disposal Of Current Financial Instruments And Paid Interests, Classified As Investing Activities" } } }, "auth_ref": [] }, "ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposals", "label": "Disposals, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment including right-of-use assets resulting from disposals. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r274" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share :", "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of income (loss) per share", "label": "Earnings per share [text block]" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r28" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of the exchange rate changes", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r41", "r42" ] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Personnel expenses", "label": "Employee benefits expense" } } }, "auth_ref": [ "r132", "r192", "r228", "r265" ] }, "inpha_EmployeeDepartureCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "EmployeeDepartureCompensationMember", "presentation": [ "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee departure compensation", "label": "Employee Departure Compensation [Member]", "documentation": "Employee Departure Compensation" } } }, "auth_ref": [] }, "inpha_EmployerContributionRateOnShareBasedPayments": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "EmployerContributionRateOnShareBasedPayments", "presentation": [ "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contribution rate on share based payments", "label": "Employer Contribution Rate On Share Based Payments", "documentation": "Employer Contribution Rate On Share Based Payments" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r271" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.innate-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r271" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "terseLabel": "Total shareholders\u2019 equity", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r48", "r50", "r63", "r64", "r65", "r157", "r165", "r180", "r181", "r190", "r206", "r215" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r206" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Equity and liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EstimatedFinancialEffectOfContingentLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated financial effect of contingent liabilities", "label": "Estimated financial effect of contingent liabilities" } }, "en": { "role": { "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r33", "r160" ] }, "inpha_ExerciseAndSubscriptionOfEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ExerciseAndSubscriptionOfEquityInstruments", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise and subscription of equity instruments", "label": "Exercise And Subscription Of Equity Instruments", "documentation": "The increase (decrease) in equity resulting from exercise and subscription of equity instruments." } } }, "auth_ref": [] }, "inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ExerciseAndSubscriptionOfEquityInstrumentsInShares", "presentation": [ "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise and subscription of equity instruments (in shares)", "label": "Exercise And Subscription Of Equity Instruments, In Shares", "documentation": "The increase (decrease) in the number of shares issued resulting from exercise and subscription of equity instruments." } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share-based compensation", "label": "Expense from share-based payment transactions with employees" } } }, "auth_ref": [ "r293" ] }, "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of change in deferred revenue and collaboration liabilities", "label": "Explanation of significant changes in contract assets and contract liabilities [text block]" } }, "en": { "role": { "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]" } } }, "auth_ref": [ "r72" ] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "FR", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets / Tax losses carryforwards - France", "label": "FRANCE" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Financial expenses", "negatedTotalLabel": "Financial expenses", "label": "Finance costs" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial income", "totalLabel": "Financial income", "label": "Finance income" } } }, "auth_ref": [ "r301" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net financial income (loss)", "label": "Finance income (cost)" } } }, "auth_ref": [ "r301" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial assets", "label": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]" } } }, "auth_ref": [ "r89", "r91", "r92", "r94", "r176", "r177", "r178", "r251" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets at amortised cost, category", "label": "Financial assets at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r102", "r171" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial assets, fair value", "label": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r89" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets at fair value through profit or loss, category", "label": "Financial assets at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r100", "r169" ] }, "inpha_FinancialAssetsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "FinancialAssetsCashAndCashEquivalentsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Financial Assets, Cash And Cash Equivalents [Member]", "documentation": "Financial Assets, Cash And Cash Equivalents" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets pledged as collateral for liabilities or contingent liabilities", "label": "Financial assets pledged as collateral for liabilities or contingent liabilities" } }, "en": { "role": { "documentation": "The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Classes of contingent liabilities [domain]; Financial assets]" } } }, "auth_ref": [ "r87", "r174" ] }, "inpha_FinancialAssetsShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "FinancialAssetsShortTermInvestmentsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Financial Assets, Short-Term Investments [Member]", "documentation": "Financial Assets, Short-Term Investments" } } }, "auth_ref": [] }, "inpha_FinancialCovenantCapitalRiskMarginPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "FinancialCovenantCapitalRiskMarginPercentage", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial covenant capital risk margin, percentage", "label": "Financial Covenant Capital Risk Margin, Percentage", "documentation": "Financial Covenant Capital Risk Margin, Percentage" } } }, "auth_ref": [] }, "inpha_FinancialCovenantMinimumFinancialAssetsThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "FinancialCovenantMinimumFinancialAssetsThreshold", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial covenant minimum financial assets threshold", "label": "Financial Covenant Minimum Financial Assets Threshold", "documentation": "Financial Covenant Minimum Financial Assets Threshold" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r89" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities at amortised cost, category", "label": "Financial liabilities at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r103", "r172" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities at fair value through profit or loss, category", "label": "Financial liabilities at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r101", "r170" ] }, "inpha_FinancialLiabilitiesCurrentPortionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "FinancialLiabilitiesCurrentPortionMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities\u2014current portion", "label": "Financial Liabilities, Current Portion [Member]", "documentation": "This member stands for financial liabilities\u2014current portion." } } }, "auth_ref": [] }, "inpha_FinancialLiabilitiesNonCurrentPortionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "FinancialLiabilitiesNonCurrentPortionMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities\u2014non-current portion", "label": "Financial Liabilities, Non-current Portion [Member]", "documentation": "This member stands for financial liabilities\u2014non-current portion." } } }, "auth_ref": [] }, "inpha_FinancialLiabilitiesTradePayablesAndOthers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "FinancialLiabilitiesTradePayablesAndOthers", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial liabilities", "label": "Financial Liabilities, Trade Payables And Others", "documentation": "The amount of financial liabilities, trade payables and others." } } }, "auth_ref": [] }, "inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "FinancialLiabilitiesTradePayablesAndOthersAtFairValue", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial liabilities, fair value", "label": "Financial Liabilities, Trade Payables And Others, At Fair Value", "documentation": "The fair value of financial liabilities, trade payables and other." } } }, "auth_ref": [] }, "ifrs-full_FixedInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FixedInterestRateMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate", "label": "Fixed interest rate [member]" } }, "en": { "role": { "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r287" ] }, "ifrs-full_ForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign exchange gains", "label": "Foreign exchange gain" } } }, "auth_ref": [ "r16", "r152", "r199" ] }, "inpha_ForeignExchangeGainLossContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ForeignExchangeGainLossContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange impact", "label": "Foreign Exchange Gain (Loss), Contract Liabilities", "documentation": "Foreign Exchange Gain (Loss), Contract Liabilities" } } }, "auth_ref": [] }, "inpha_ForeignExchangeGainLossCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ForeignExchangeGainLossCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange impact", "label": "Foreign Exchange Gain (Loss), Current Contract Liabilities", "documentation": "Foreign exchange gain (loss), Current Contract Liabilities" } } }, "auth_ref": [] }, "inpha_ForeignExchangeGainLossNonCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ForeignExchangeGainLossNonCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange impact", "label": "Foreign Exchange Gain (Loss), Non Current Contract Liabilities", "documentation": "Foreign Exchange Gain (Loss), Non Current Contract Liabilities" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign exchange losses", "label": "Foreign exchange loss" } } }, "auth_ref": [ "r16", "r152", "r199" ] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Actuarial (gain) / loss", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r13", "r151" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "General and administrative expenses", "label": "General and administrative expense" } } }, "auth_ref": [ "r293" ] }, "inpha_GovernmentFinancingForResearchExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "GovernmentFinancingForResearchExpenditures", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government financing for research expenditures", "totalLabel": "Government financing for research expenditures", "label": "Government Financing For Research Expenditures", "documentation": "The amount of income recognised in relation to government financing for research expenditures." } } }, "auth_ref": [] }, "ifrs-full_GuaranteesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GuaranteesMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantees", "label": "Guarantees [member]" } }, "en": { "role": { "documentation": "This member stands for formal promises, often in writing, in which one party assumes responsibility for another's debts or responsibilities, or in which the party provides assurance that certain conditions will be fulfilled." } } }, "auth_ref": [ "r254" ] }, "inpha_IncomeFromResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncomeFromResearchTaxCredit", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails": { "parentTag": "inpha_GovernmentFinancingForResearchExpenditures", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit", "label": "Income From Research Tax Credit", "documentation": "The amount of income related to research tax credit." } } }, "auth_ref": [] }, "inpha_IncomeLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncomeLossPerShareAbstract", "lang": { "en-us": { "role": { "label": "Income (Loss) Per Share [Abstract]" } } }, "auth_ref": [] }, "inpha_IncomeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncomeTaxAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax [Abstract]", "label": "Income Tax [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense", "label": "Tax expense (income)" } } }, "auth_ref": [ "r2", "r3", "r4", "r27", "r62", "r111", "r142", "r143", "r144", "r225" ] }, "inpha_IncreaseCapitalNetInShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncreaseCapitalNetInShares", "presentation": [ "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase capital, net (In Shares)", "label": "Increase Capital, Net (In Shares)", "documentation": "Increase Capital, Net (In Shares)" } } }, "auth_ref": [] }, "inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": "inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments, variation of accrued interest", "label": "Increase (Decrease) In Accrued Interest For Current Financial Assets Not At Fair Value Through Profit Or Loss", "documentation": "The amount of income arising from interest for current financial assets that are not at fair value through profit or loss." } } }, "auth_ref": [] }, "inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": "inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets, variation of accrued interest", "label": "Increase (Decrease) In Accrued Interest For Non-current Financial Assets Not At Fair Value Through Profit Or Loss", "documentation": "The amount of income arising from interest for non-current financial assets that are not at fair value through profit or loss." } } }, "auth_ref": [] }, "inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total variance of accrued interest", "label": "Increase (Decrease) In Accrued Interest For Short-term And Non-current Financial Assets Not At Fair Value Through Profit Or Loss", "documentation": "The amount of income arising from interest for short-term and non-current financial assets that are not at fair value through profit or loss." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase / (decrease) in cash and cash equivalents:", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r45", "r138" ] }, "inpha_IncreaseDecreaseInRevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncreaseDecreaseInRevenueFromContractsWithCustomers", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in revenue from contracts with customers", "label": "Increase (Decrease) In Revenue From Contracts With Customers", "documentation": "Increase (Decrease) In Revenue From Contracts With Customers" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in working capital", "negatedTotalLabel": "Total change in working capital, variance", "label": "Increase (decrease) in working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r285" ] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation of prior period income (loss)", "label": "Increase (decrease) through appropriation of retained earnings, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r291" ] }, "inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncreaseDecreaseThroughForeignExchangeFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange rate variation (non cash)", "label": "Increase (Decrease) Through Foreign Exchange, Financial Liabilities", "documentation": "Increase (Decrease) Through Foreign Exchange, Financial Liabilities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange variation", "label": "Increase (decrease) through net exchange differences, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment including right-of-use assets resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r274" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shared-based payment", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r196" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfers", "label": "Increase (decrease) through transfers from construction in progress, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment including right-of-use assets resulting from transfers from construction in progress. [Refer: Property, plant and equipment including right-of-use assets; Construction in progress]" } } }, "auth_ref": [ "r274" ] }, "inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Increase Through Performance Obligation Being Satisfied, Contract Liabilities", "documentation": "The increase in contract liabilities resulting from additions." } } }, "auth_ref": [] }, "inpha_IncreaseThroughPerformanceObligationBeingSatisfiedCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncreaseThroughPerformanceObligationBeingSatisfiedCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Increase Through Performance Obligation Being Satisfied, Current Contract Liabilities", "documentation": "Increase Through Performance Obligation Being Satisfied, Current Contract Liabilities" } } }, "auth_ref": [] }, "inpha_IncreaseThroughPerformanceObligationBeingSatisfiedNonCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncreaseThroughPerformanceObligationBeingSatisfiedNonCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Increase Through Performance Obligation Being Satisfied, Non Current Contract Liabilities", "documentation": "Increase Through Performance Obligation Being Satisfied, Non Current Contract Liabilities" } } }, "auth_ref": [] }, "inpha_IncreaseThroughUpfrontPaymentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IncreaseThroughUpfrontPaymentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds", "label": "Increase Through Upfront Payment, Contract Liabilities", "documentation": "The increase in contract liabilities resulting from upfront payment." } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "verboseLabel": "Intangible assets other than goodwill", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r35", "r162", "r200" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "inpha_IntellectualPropertyExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "IntellectualPropertyExpenses", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Intellectual property expenses", "label": "Intellectual Property Expenses", "documentation": "The amount of intellectual property expenses." } } }, "auth_ref": [] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Paid Interests on financial liabilities", "label": "Interest expense" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r61", "r109", "r116" ] }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsOperatingActivities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid, classified as operating activities", "label": "Interest paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } } }, "auth_ref": [ "r43" ] }, "inpha_InterestReceivedAdjustmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "InterestReceivedAdjustmentClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received on financial assets", "label": "Interest Received Adjustment, Classified As Investing Activities", "documentation": "Interest Received Adjustment, Classified As Investing Activities" } } }, "auth_ref": [] }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsOperatingActivities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "label": "Interest received, classified as operating activities" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } } }, "auth_ref": [ "r43" ] }, "inpha_InterestsAndGainsOnFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "InterestsAndGainsOnFinancialAssets", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interests and gain on financial assets", "label": "Interests And Gains On Financial Assets", "documentation": "The amount of interests and gains on financial assets." } } }, "auth_ref": [] }, "inpha_InvoicingResearchAndDevelopmentCostsIPH5201Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "InvoicingResearchAndDevelopmentCostsIPH5201Member", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPH5201 agreement, with AstraZeneca", "label": "Invoicing Research And Development Costs IPH5201 [Member]", "documentation": "Invoicing Research And Development Costs IPH5201" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Capital Increase", "verboseLabel": "Issue of equity", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r196" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r264", "r270" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails", "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r197" ] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Executive Board Members and other Executive Members compensation", "label": "Key management personnel compensation" } } }, "auth_ref": [ "r20", "r153" ] }, "inpha_KeyManagementPersonnelCompensationAdvisoryFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "KeyManagementPersonnelCompensationAdvisoryFees", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advisory fees", "label": "Key Management Personnel Compensation, Advisory Fees", "documentation": "Key Management Personnel Compensation, Advisory Fees" } } }, "auth_ref": [] }, "inpha_KeyManagementPersonnelCompensationExtraPensionBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "KeyManagementPersonnelCompensationExtraPensionBenefits", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Extra pension benefits", "label": "Key Management Personnel Compensation, Extra Pension Benefits", "documentation": "Key Management Personnel Compensation, Extra Pension Benefits" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "Key management personnel compensation, share-based payment" } } }, "auth_ref": [ "r19" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Personnel and other short-term employee benefits", "label": "Key management personnel compensation, short-term employee benefits" } } }, "auth_ref": [ "r18" ] }, "inpha_LaboratoryEquipmentAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LaboratoryEquipmentAndOtherMember", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment and other", "label": "Laboratory Equipment And Other [Member]", "documentation": "This member stands for laboratory equipment and other." } } }, "auth_ref": [] }, "ifrs-full_LandAndBuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LandAndBuildingsMember", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lands and buildings", "label": "Land and buildings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]" } } }, "auth_ref": [ "r230" ] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Over 5 years", "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r76", "r77", "r81", "r127", "r130", "r252", "r255", "r257" ] }, "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "From 4th to 5th year included", "label": "Later than four years and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than four years and not later than five years." } } }, "auth_ref": [ "r76", "r77", "r81", "r252", "r257", "r293" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "From 1st to 2nd year included", "label": "Later than one year and not later than two years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r76", "r77", "r81", "r252", "r257", "r293" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "From 3th to 4th year included", "label": "Later than three years and not later than four years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } } }, "auth_ref": [ "r76", "r77", "r81", "r252", "r257", "r293" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "From 2nd to 3th year included", "label": "Later than two years and not later than three years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } } }, "auth_ref": [ "r76", "r77", "r81", "r252", "r257", "r293" ] }, "inpha_LeaseContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LeaseContractMember", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities / Lease contract (IFRS 16 application)", "label": "Lease Contract [Member]", "documentation": "Lease Contract" } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsBuildingLeVirageMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LeaseFinancingObligationsBuildingLeVirageMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities \u2013 Building \"Le Virage\"", "label": "Lease Financing Obligations, Building, \"Le Virage\" [Member]", "documentation": "Related to the finance lease obligations for the \"Le Virage\" building." } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LeaseFinancingObligationsEquipmentMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities \u2013 Laboratory equipment", "label": "Lease Financing Obligations, Equipment [Member]", "documentation": "This member stands for lease finance obligations, equipment." } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsInnateIncPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LeaseFinancingObligationsInnateIncPremisesMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities \u2013 Premises Innate Inc.", "label": "Lease Financing Obligations, Innate Inc. Premises [Member]", "documentation": "Related to the lease financing obligations for the Innate Inc. premises." } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsMerakiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LeaseFinancingObligationsMerakiMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities - Meraki", "label": "Lease Financing Obligations, Meraki [Member]", "documentation": "Lease Financing Obligations, Meraki" } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsPrintersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LeaseFinancingObligationsPrintersMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities - Printers", "label": "Lease Financing Obligations, Printers [Member]", "documentation": "Lease Financing Obligations, Printers" } } }, "auth_ref": [] }, "inpha_LeaseFinancingObligationsVehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LeaseFinancingObligationsVehiclesMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities \u2013 Vehicles", "label": "Lease Financing Obligations, Vehicles [Member]", "documentation": "Related to the lease financing obligation for vehicles." } } }, "auth_ref": [] }, "inpha_LeasingAndMaintenance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LeasingAndMaintenance", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Leasing and maintenance", "label": "Leasing And Maintenance", "documentation": "The amount of leasing and maintenance." } } }, "auth_ref": [] }, "ifrs-full_LegalProceedingsProvisionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LegalProceedingsProvisionMember", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal proceedings provision", "label": "Legal proceedings provision [member]" } }, "en": { "role": { "documentation": "This member stands for a provision for legal proceedings. [Refer: Classes of other provisions [domain]]" } } }, "auth_ref": [ "r235", "r236" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Net defined benefit liability (asset) at beginning of period", "periodEndLabel": "Net defined benefit liability (asset) at end of period", "label": "Net defined benefit liability (asset)" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r11", "r149" ] }, "inpha_LoanAgreementCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LoanAgreementCollateral", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan agreement, collateral", "label": "Loan Agreement Collateral", "documentation": "The value of collateral in connection with the loan agreement." } } }, "auth_ref": [] }, "inpha_LoanAgreementMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LoanAgreementMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan agreement, maximum borrowing capacity", "label": "Loan Agreement Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the loan agreement." } } }, "auth_ref": [] }, "inpha_LoanAgreementWithSocitGnraleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LoanAgreementWithSocitGnraleMember", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan agreement with Soci\u00e9t\u00e9 G\u00e9n\u00e9rale", "label": "Loan Agreement With Soci\u00e9t\u00e9 G\u00e9n\u00e9rale [Member]", "documentation": "This member stands for loan agreement with Soci\u00e9t\u00e9 G\u00e9n\u00e9rale." } } }, "auth_ref": [] }, "inpha_LoanBuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LoanBuildingMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing \u2013 Building", "label": "Loan, Building [Member]", "documentation": "This member stands for loan, building." } } }, "auth_ref": [] }, "inpha_LoanEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "LoanEquipmentMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing \u2013 Equipment", "label": "Loan, Equipment [Member]", "documentation": "This member stands for loan, equipment." } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r95", "r179" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [axis]", "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r73", "r76", "r77", "r78", "r79", "r80", "r81", "r88", "r96", "r122", "r125", "r128", "r131", "r175", "r209", "r232", "r252" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [domain]", "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r73", "r76", "r77", "r78", "r79", "r80", "r81", "r88", "r122", "r125", "r128", "r131", "r175", "r209", "r232", "r252", "r256" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [] }, "inpha_MonalizumabAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "MonalizumabAgreementMember", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Monalizumab agreement (AstraZeneca)", "terseLabel": "Monalizumab agreement", "label": "Monalizumab Agreement [Member]", "documentation": "This member stands for monalizumab agreement." } } }, "auth_ref": [] }, "inpha_MonalizumabMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "MonalizumabMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monalizumab", "label": "Monalizumab [Member]", "documentation": "This member stands for Monalizumab." } } }, "auth_ref": [] }, "inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember", "presentation": [ "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2014 Monalizumab (NKG2A) agreement with Novo Nordisk", "label": "Monalizumab Rights Under The 2014 Monalizumab (NKG2A) Novo Nordisk Agreement [Member]", "documentation": "This member stands for Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement." } } }, "auth_ref": [] }, "inpha_NearTermDevelopmentMilestonePaymentsEligible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NearTermDevelopmentMilestonePaymentsEligible", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nearterm development milestone payments eligible", "label": "NearTerm Development Milestone Payments Eligible", "documentation": "NearTerm Development Milestone Payments Eligible" } } }, "auth_ref": [] }, "inpha_NetAmountsReceivablePayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NetAmountsReceivablePayableRelatedPartyTransactions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net receivables (liabilities)", "label": "Net Amounts Receivable (Payable) Related Party Transactions", "documentation": "The net amounts of receivables (payable) resulting from related party transactions." } } }, "auth_ref": [] }, "inpha_NetCashAdvanceReceivedFromMadeToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NetCashAdvanceReceivedFromMadeToRelatedParties", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net collection (payments)", "label": "Net Cash Advance Received From (Made To) Related Parties", "documentation": "Net Cash Advance Received From (Made To) Related Parties" } } }, "auth_ref": [] }, "inpha_NonCancellableOffBalanceSheetPurchasedCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NonCancellableOffBalanceSheetPurchasedCommitments", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cancellable off-balance sheet purchase commitments", "label": "Non Cancellable Off Balance Sheet Purchased Commitments", "documentation": "Represents the amount of non-cancellable off-balance sheet purchase commitments as of the specified date." } } }, "auth_ref": [] }, "inpha_NonCurrentFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NonCurrentFinancialAssetsAbstract", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets", "label": "Non-Current Financial Assets [Abstract]", "documentation": "Non-Current Financial Assets" } } }, "auth_ref": [] }, "inpha_NonCurrentFinancialAssetsAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NonCurrentFinancialAssetsAcquisitions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": "inpha_TotalAcquisitions", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets, acquisitions", "label": "Non-current Financial Assets, Acquisitions", "documentation": "The increase in non-current financial assets resulting from origination or purchase." } } }, "auth_ref": [] }, "inpha_NonCurrentFinancialAssetsForeignCurrencyEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NonCurrentFinancialAssetsForeignCurrencyEffect", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": "inpha_TotalForeignCurrencyEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets, foreign currency effect", "label": "Non-current Financial Assets, Foreign Currency Effect", "documentation": "The increase (decrease) in non-current financial assets resulting from foreign exchange and other movements." } } }, "auth_ref": [] }, "inpha_NonCurrentFinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NonCurrentFinancialAssetsMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets", "label": "Non-current Financial Assets [Member]", "documentation": "This member stands for non-current financial assets." } } }, "auth_ref": [] }, "inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": "inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails", "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets, variation of fair value through the consolidated statement of income (loss)", "label": "Non-current Financial Assets, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)", "documentation": "The gains (losses) on non-current financial assets at fair value through profit or loss." } } }, "auth_ref": [] }, "inpha_NonCurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NonCurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Non-Current Prepaid Expenses", "documentation": "Non-Current Prepaid Expenses" } } }, "auth_ref": [] }, "inpha_NonCurrentResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NonCurrentResearchTaxCredit", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research tax credit", "label": "Non-Current Research Tax Credit", "documentation": "The amount of non-current research tax credit." } } }, "auth_ref": [] }, "inpha_NonCurrentResearchTaxCredit2025": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NonCurrentResearchTaxCredit2025", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current research tax credit, 2025", "label": "Non-Current Research Tax Credit, 2025", "documentation": "Non-Current Research Tax Credit, 2025" } } }, "auth_ref": [] }, "inpha_NonScientificAdvisoryAndConsulting": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NonScientificAdvisoryAndConsulting", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-scientific advisory and consulting", "label": "Non-scientific Advisory And Consulting", "documentation": "The amount of non-scientific advisory and consulting." } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [axis]", "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r141" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period", "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r141" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r53", "r210", "r243" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Non-current contract liabilities at the beginning of period", "periodEndLabel": "Non-current contract liabilities s at end of period", "label": "Non-current contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r68" ] }, "ifrs-full_NoncurrentContractLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentContractLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Current", "label": "Non-current contract liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue \u2013 non-current portion", "label": "Non-current deferred income including non-current contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current deferred income including non-current contract liabilities. [Refer: Deferred income including contract liabilities]" } } }, "auth_ref": [ "r296", "r299" ] }, "ifrs-full_NoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails": { "parentTag": "inpha_TotalCashCashEquivalentsAndFinancialAssets", "weight": 1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails", "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current financial assets", "periodStartLabel": "Beginning balance, non-current financial assets", "periodEndLabel": "Ending balance, non-current financial assets", "label": "Non-current financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r89" ] }, "ifrs-full_NoncurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities \u2013 non-current portion", "label": "Non-current financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r89" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r55", "r211", "r243" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPrepayments", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments made to suppliers", "label": "Non-current prepayments" } }, "en": { "role": { "documentation": "The amount of non-current prepayments. [Refer: Prepayments]" } } }, "auth_ref": [ "r263", "r269" ] }, "ifrs-full_NoncurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisions", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions - non-current portion", "label": "Non-current provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r204" ] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit obligations", "label": "Non-current provisions for employee benefits" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r189", "r214" ] }, "ifrs-full_NoncurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others - non-current", "totalLabel": "Receivables and others - non-current", "label": "Trade and other non-current receivables" } }, "en": { "role": { "documentation": "The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]" } } }, "auth_ref": [ "r188", "r201", "r213" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Within 1 year", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r76", "r77", "r81", "r126", "r129", "r208", "r252", "r257" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Notional amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r293" ] }, "inpha_NovoNordiskASMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NovoNordiskASMember", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Novo Nordisk A/S", "label": "Novo Nordisk A/S [Member]", "documentation": "This member stands for Novo Nordisk A/S." } } }, "auth_ref": [] }, "inpha_NumberOfCollaborationContracts": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NumberOfCollaborationContracts", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of collaboration contracts", "label": "Number Of Collaboration Contracts", "documentation": "Number Of Collaboration Contracts" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails", "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employees", "label": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r293" ] }, "inpha_NumberOfExclusiveOptionsGranted": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NumberOfExclusiveOptionsGranted", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of exclusive options granted", "label": "Number Of Exclusive Options Granted", "documentation": "Number Of Exclusive Options Granted" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails", "http://www.innate-pharma.com/role/IncomelosspershareDilutedincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of free shares granted (in shares)", "netLabel": "Number of other equity instruments", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r85", "r286" ] }, "inpha_NumberOfLicensingAgreementsWithRelatedParties": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NumberOfLicensingAgreementsWithRelatedParties", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of licensing agreements", "label": "Number Of Licensing Agreements With Related Parties", "documentation": "Number Of Licensing Agreements With Related Parties" } } }, "auth_ref": [] }, "inpha_NumberOfLoans": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NumberOfLoans", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of loans", "label": "Number Of Loans", "documentation": "Number Of Loans" } } }, "auth_ref": [] }, "inpha_NumberOfMutualFundsInWhichTheEntityIsHoldingShares": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NumberOfMutualFundsInWhichTheEntityIsHoldingShares", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of mutual funds in which the entity is holding shares", "label": "Number Of Mutual Funds In Which the Entity is Holding Shares", "documentation": "Number Of Mutual Funds In Which the Entity is Holding Shares" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement (in shares)", "label": "Number of other equity instruments exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r286" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r286" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments forfeited in share-based payment arrangement (in shares)", "label": "Number of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r286" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other equity instruments outstanding in share-based payment arrangement (in shares)", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r286" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "verboseLabel": "Number of shares issued (in shares)", "terseLabel": "Total number of shares issued (in shares)", "label": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r291" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails", "http://www.innate-pharma.com/role/IncomelosspershareDilutedincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares outstanding (in shares)", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r134", "r184", "r217" ] }, "inpha_NumberOfTargetOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NumberOfTargetOptions", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of target options", "label": "Number Of Target Options", "documentation": "Number Of Target Options" } } }, "auth_ref": [] }, "inpha_NumberOfTherapeuticApproaches": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NumberOfTherapeuticApproaches", "presentation": [ "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of therapeutic approaches", "label": "Number Of Therapeutic Approaches", "documentation": "Number Of Therapeutic Approaches" } } }, "auth_ref": [] }, "inpha_NumberOfWhollyOwnedSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "NumberOfWhollyOwnedSubsidiaries", "presentation": [ "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of subsidiaries", "label": "Number Of Wholly Owned Subsidiaries", "documentation": "Number Of Wholly Owned Subsidiaries" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Operating expenses", "label": "Operating expense" } } }, "auth_ref": [ "r301" ] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r300" ] }, "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAdjustmentsToReconcileProfitLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other profit or loss items with no cash effect", "label": "Other adjustments to reconcile profit (loss)" } } }, "auth_ref": [ "r40" ] }, "inpha_OtherAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "OtherAgreementsMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other agreement", "label": "Other Agreements [Member]", "documentation": "This member stands for other agreement." } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "label": "Other comprehensive income" } } }, "auth_ref": [ "r58", "r195", "r221", "r226" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 }, "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation gain (loss)", "verboseLabel": "Foreign currency translation loss", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r212", "r226" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gains and (losses) related to defined benefit obligations", "verboseLabel": "Actuarial gains (losses) on defined benefit obligations", "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r212", "r226", "r275" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other payables", "label": "Other current payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r296" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other receivables", "label": "Other current receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r263", "r269" ] }, "inpha_OtherCurrentTaxCreditsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "OtherCurrentTaxCreditsReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other tax credits", "label": "Other Current Tax Credits Receivables", "documentation": "The amount of other current tax credits receivables." } } }, "auth_ref": [] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other income" } } }, "auth_ref": [ "r26", "r265", "r266" ] }, "ifrs-full_OtherNoncurrentNonfinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentNonfinancialAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other non-current non-financial assets" } }, "en": { "role": { "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income and (expenses), net", "label": "Other operating income (expense)" } } }, "auth_ref": [ "r301" ] }, "inpha_OtherPurchasesAndExternalExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "OtherPurchasesAndExternalExpenses", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other purchases and external expenses", "label": "Other Purchases And External Expenses", "documentation": "The amount of other purchases and external expenses." } } }, "auth_ref": [] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "verboseLabel": "Other reserves", "label": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r264", "r270" ] }, "ifrs-full_OtherTemporaryDifferencesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherTemporaryDifferencesMember", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other temporary differences", "label": "Other temporary differences [member]" } }, "en": { "role": { "documentation": "This member stands for temporary differences that the entity does not separately disclose in the same statement or note. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r272" ] }, "inpha_PGELoanAgreementAccruedInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "PGELoanAgreementAccruedInterestMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State guaranteed loans - accrued interest", "label": "PGE Loan Agreement, Accrued Interest [Member]", "documentation": "PGE Loan Agreement, Accrued Interest" } } }, "auth_ref": [] }, "inpha_PGELoanAgreementBNPParibasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "PGELoanAgreementBNPParibasMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State guaranteed loan BNP Paribas", "label": "PGE Loan Agreement, BNP Paribas [Member]", "documentation": "PGE Loan Agreement, BNP Paribas" } } }, "auth_ref": [] }, "inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "PGELoanAgreementSocieteGeneraleAndBNPParibasMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/TradepayablesandothersDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State guaranteed loan, Societe Generale and BNP Paribas", "label": "PGE Loan Agreement, Societe Generale And BNP Paribas [Member]", "documentation": "PGE Loan Agreement, Societe Generale And BNP Paribas" } } }, "auth_ref": [] }, "inpha_PGELoanAgreementSocieteGeneraleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "PGELoanAgreementSocieteGeneraleMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State guaranteed loan Soci\u00e9t\u00e9 G\u00e9n\u00e9rale", "label": "PGE Loan Agreement, Societe Generale [Member]", "documentation": "PGE Loan Agreement, Societe Generale" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Par value per share (in EUR per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r133", "r183", "r216" ] }, "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax and employee-related payables", "label": "Payables on social security and taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity." } } }, "auth_ref": [ "r299" ] }, "inpha_PercentageOfPreFinancedCIRCollected2023And2024": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "PercentageOfPreFinancedCIRCollected2023And2024", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of prefinanced CIR collected", "label": "Percentage Of Pre Financed CIR Collected 2023 And 2024", "documentation": "Percentage Of Pre Financed CIR Collected 2023 And 2024" } } }, "auth_ref": [] }, "inpha_PledgedCollateralMarginPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "PledgedCollateralMarginPercentage", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pledged collateral margin percentage", "label": "Pledged Collateral Margin Percentage", "documentation": "Pledged Collateral Margin Percentage" } } }, "auth_ref": [] }, "inpha_PreclinicalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "PreclinicalServicesMember", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preclinical Services", "label": "Preclinical Services [Member]", "documentation": "Preclinical Services" } } }, "auth_ref": [] }, "ifrs-full_PreferenceSharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PreferenceSharesMember", "presentation": [ "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Shares", "label": "Preference shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r300" ] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowing", "label": "Proceeds from borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r240" ] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issue of ordinary shares", "label": "Proceeds from issue of ordinary shares" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r282" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the exercise / subscription of equity instruments", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r239" ] }, "inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from lease liabilities and other non cash effects", "label": "Proceeds From Lease Liabilities, Classified As Financing Activities", "documentation": "The amount of proceeds from lease liabilities." } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal of other assets", "label": "Proceeds from sales of other long-term assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]" } } }, "auth_ref": [ "r238" ] }, "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal of property and equipment", "label": "Proceeds from sales of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r238" ] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and services [axis]", "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r117", "r247", "r260" ] }, "ifrs-full_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and services", "label": "Products and services [domain]" } }, "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r117", "r247", "r260" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 }, "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity", "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss) for the period:", "terseLabel": "Net income (loss)", "negatedLabel": "Net loss for the period", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r49", "r51", "r112", "r114", "r158", "r166", "r194", "r220", "r243", "r249" ] }, "ifrs-full_ProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAbstract", "lang": { "en-us": { "role": { "label": "Profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) before tax", "label": "Profit (loss) before tax" } } }, "auth_ref": [ "r86", "r258", "r259", "r265", "r266" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income (loss)", "label": "Profit (loss) from operating activities" } } }, "auth_ref": [ "r233", "r301" ] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "periodStartLabel": "Property, plant and equipment including right-of-use assets at beginning of period", "periodEndLabel": "Property, plant and equipment including right-of-use assets at end of period", "label": "Property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]" } } }, "auth_ref": [ "r75", "r274", "r295" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment including right-of-use assets [axis]", "label": "Property, plant and equipment including right-of-use assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r274" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment including right-of-use assets [domain]", "label": "Property, plant and equipment including right-of-use assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a class of asset representing property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r274" ] }, "inpha_ProvisionForAttendanceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ProvisionForAttendanceFees", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for attendance fees", "label": "Provision For Attendance Fees", "documentation": "The amount of provision for attendance fees." } } }, "auth_ref": [] }, "inpha_ProvisionForDefinedBenefitObligationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ProvisionForDefinedBenefitObligationMember", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets / Provision for defined benefit obligation", "label": "Provision for defined benefit obligation [Member]", "documentation": "Provision for defined benefit obligation" } } }, "auth_ref": [] }, "inpha_ProvisionForExpensesWithRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ProvisionForExpensesWithRelatedParties", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for expenses with related parties", "label": "Provision For Expenses With Related Parties", "documentation": "Provision For Expenses With Related Parties" } } }, "auth_ref": [] }, "ifrs-full_Provisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Provisions", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Provisions" } }, "en": { "role": { "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits." } } }, "auth_ref": [ "r204" ] }, "inpha_ProvisionsForEmployeeBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ProvisionsForEmployeeBenefitsMember", "presentation": [ "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions for employee benefits", "label": "Provisions For Employee Benefits [Member]", "documentation": "Provisions For Employee Benefits" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of other assets", "label": "Purchase of other long-term assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]" } } }, "auth_ref": [ "r237" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of property and equipment, net", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r237" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [axis]", "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r44", "r67", "r80", "r83", "r137", "r244", "r245", "r288" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ranges [member]", "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r44", "r67", "r80", "r83", "r137", "r244", "r245", "r288" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "ifrs-full_RawMaterialsAndConsumablesUsed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RawMaterialsAndConsumablesUsed", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost of supplies and consumable materials", "label": "Raw materials and consumables used" } } }, "auth_ref": [ "r228", "r265" ] }, "inpha_ReclassificationContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ReclassificationContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Reclassification, Contract Liabilities", "documentation": "Reclassification, Contract Liabilities" } } }, "auth_ref": [] }, "inpha_ReclassificationCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ReclassificationCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Reclassification, Current Contract Liabilities", "documentation": "Reclassification, Current Contract Liabilities" } } }, "auth_ref": [] }, "inpha_ReclassificationNonCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ReclassificationNonCurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Reclassification, Non Current Contract Liabilities", "documentation": "Reclassification, Non Current Contract Liabilities" } } }, "auth_ref": [] }, "ifrs-full_RecognisedAssetsDefinedBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RecognisedAssetsDefinedBenefitPlan", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net defined benefit asset", "label": "Net defined benefit asset" } }, "en": { "role": { "documentation": "The amount of surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]", "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "inpha_RegulatoryAndCommercialMilestonePaymentsEligible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "RegulatoryAndCommercialMilestonePaymentsEligible", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory and commercial milestone payments eligible", "label": "Regulatory And Commercial Milestone Payments Eligible", "documentation": "Regulatory And Commercial Milestone Payments Eligible" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related party transactions [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of borrowings", "label": "Repayments of borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r241" ] }, "inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of borrowings/leases liabilities", "label": "Repayments Of Borrowings Net Of Exchange Rate Variation, Classified As Financing Activities", "documentation": "Repayments Of Borrowings Net Of Exchange Rate Variation, Classified As Financing Activities" } } }, "auth_ref": [] }, "inpha_ResearchActivitiesPerformancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ResearchActivitiesPerformancePeriod", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research activities performance period", "label": "Research Activities Performance Period", "documentation": "Research Activities Performance Period" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development expenses", "label": "Research and development expense" } } }, "auth_ref": [ "r37", "r164" ] }, "inpha_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails", "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D", "label": "Research And Development [Member]", "documentation": "Research And Development" } } }, "auth_ref": [] }, "inpha_ResearchTaxCreditReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ResearchTaxCreditReceivableCurrent", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit", "label": "Research Tax Credit, Receivable, Current", "documentation": "Research Tax Credit, Receivable, Current" } } }, "auth_ref": [] }, "ifrs-full_RestructuringProvisionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestructuringProvisionMember", "presentation": [ "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring provision", "label": "Restructuring provision [member]" } }, "en": { "role": { "documentation": "This member stands for a provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Classes of other provisions [domain]]" } } }, "auth_ref": [ "r234" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained earnings, excluding profit (loss) for reporting period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]" } } }, "auth_ref": [ "r298" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodMember", "presentation": [ "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained earnings, excluding profit (loss) for reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit, excluding profit or loss for the reporting period. [Refer: Retained earnings [member]]" } } }, "auth_ref": [ "r292" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Retained earnings, profit (loss) for reporting period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r298" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Retained earnings, profit (loss) for reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r292" ] }, "inpha_RetirementDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "RetirementDefinedBenefitMember", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails", "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for retirement defined benefit", "label": "Retirement Defined Benefit [Member]", "documentation": "This member stands for retirement defined benefit." } } }, "auth_ref": [] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Revenue and other income", "label": "Revenue" } } }, "auth_ref": [ "r57", "r86", "r108", "r113", "r117", "r118", "r119", "r223", "r243", "r265", "r266" ] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss", "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from collaboration and licensing agreements", "label": "Revenue from contracts with customers" } } }, "auth_ref": [ "r69", "r70", "r123" ] }, "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceived", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance received", "label": "Revenue From Contracts With Customers, Advance Payment Received", "documentation": "The amount of advance received by the company." } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance received - exclusive license", "label": "Revenue From Contracts With Customers, Advance Payment Received, Licenses", "documentation": "The cash outflow for licenses." } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for research work", "label": "Revenue From Contracts With Customers, Advance Payment Received, Research", "documentation": "Revenue From Contracts With Customers, Advance Payment Received, Research" } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for target options", "label": "Revenue From Contracts With Customers, Advance Payment Received, Target Options", "documentation": "Revenue From Contracts With Customers, Advance Payment Received, Target Options" } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "RevenueFromContractsWithCustomersMilestonePaymentReceived", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment received", "label": "Revenue From Contracts With Customers, Milestone Payment Received", "documentation": "Revenue From Contracts With Customers, Milestone Payment Received" } } }, "auth_ref": [] }, "inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment received - option exercised", "label": "Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised", "documentation": "Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromGovernmentGrants", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails": { "parentTag": "inpha_GovernmentFinancingForResearchExpenditures", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Grant", "label": "Income from government grants" } } }, "auth_ref": [ "r278" ] }, "ifrs-full_ReversalOfProvisionsForCostOfRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReversalOfProvisionsForCostOfRestructuring", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reversal of provisions for cost of restructuring", "label": "Reversal of provisions for cost of restructuring" } } }, "auth_ref": [ "r227" ] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://www.innate-pharma.com/role/PropertyandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Right-of-use assets [member]" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r74" ] }, "inpha_RiskProfileRate": { "xbrltype": "decimalItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "RiskProfileRate", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk profile rate", "label": "Risk Profile Rate", "documentation": "Risk Profile Rate" } } }, "auth_ref": [] }, "inpha_SICAVAndMutualFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SICAVAndMutualFundsMember", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SICAV and mutual funds", "label": "SICAV And Mutual Funds [Member]", "documentation": "SICAV And Mutual Funds" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Marketing, communication and public relations", "label": "Sales and marketing expense" } } }, "auth_ref": [ "r301" ] }, "inpha_SanofiAventisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SanofiAventisMember", "presentation": [ "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails", "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanofi-Aventis", "label": "Sanofi-Aventis [Member]", "documentation": "Sanofi-Aventis" } } }, "auth_ref": [] }, "inpha_SanofiOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SanofiOptionsMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanofi (2022) option", "label": "Sanofi, Options [Member]", "documentation": "Sanofi, Options" } } }, "auth_ref": [] }, "inpha_SanofiResearchCollaborationAndLicensingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SanofiResearchCollaborationAndLicensingAgreementMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement with Sanofi, 2022", "label": "Sanofi Research Collaboration And Licensing Agreement [Member]", "documentation": "Sanofi Research Collaboration And Licensing Agreement" } } }, "auth_ref": [] }, "inpha_SanofiServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SanofiServicesMember", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanofi (2022) services", "label": "Sanofi, Services [Member]", "documentation": "Sanofi, Services" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioForecastMember", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [] }, "inpha_ScientificAdvisoryAndConsulting": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ScientificAdvisoryAndConsulting", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Scientific advisory and consulting", "label": "Scientific Advisory And Consulting", "documentation": "The amount of Scientific advisory and consulting." } } }, "auth_ref": [] }, "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsReleased", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security interest on pledge of financial instruments released", "label": "Security Interest On Pledge Of Financial Instruments Released", "documentation": "The values of security interest on the pledge of financial instruments will be released in 2024." } } }, "auth_ref": [] }, "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security interest on pledge of financial instruments will be released in 2024", "label": "Security Interest On Pledge Of Financial Instruments Will Be Released In 2024", "documentation": "The values of security interest on the pledge of financial instruments will be released in 2024." } } }, "auth_ref": [] }, "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security interest on pledge of financial instruments will be released in 2027", "label": "Security Interest On Pledge Of Financial Instruments Will Be Released In 2027", "documentation": "The values of security interest on pledge of financial instruments will be released in 2027." } } }, "auth_ref": [] }, "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security interest on pledge of financial instruments will be released in 2031", "label": "Security Interest On Pledge Of Financial Instruments Will Be Released In 2031", "documentation": "The values of Security interest on pledge of financial instruments will be released in 2024." } } }, "auth_ref": [] }, "inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security interest on pledge of financial instruments released in 2024 including interest", "label": "Security Interest On Pledged Financial Instruments Released, Including Interest", "documentation": "Security Interest On Pledged Financial Instruments Released, Including Interest" } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "G&A", "label": "Selling, general and administrative expense [member]" } } }, "auth_ref": [ "r290", "r293" ] }, "inpha_SeniorityAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SeniorityAwardsMember", "presentation": [ "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for seniority awards", "label": "Seniority Awards [Member]", "documentation": "This member stands for seniority awards." } } }, "auth_ref": [] }, "inpha_ShareCapitalAndShareBasePaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ShareCapitalAndShareBasePaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share Capital and Share Base Payments [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r264", "r270" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share premium", "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r197" ] }, "ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates", "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of own shares (in shares)", "label": "Number of shares in entity held by entity or by its subsidiaries or associates" } }, "en": { "role": { "documentation": "The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Total for all associates [member]; Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r135", "r185", "r218" ] }, "inpha_ShortTermInvestments1Abstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ShortTermInvestments1Abstract", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short Term Investments1 [Abstract]", "documentation": "Short Term Investments1" } } }, "auth_ref": [] }, "inpha_ShortTermInvestmentsAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ShortTermInvestmentsAcquisitions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": "inpha_TotalAcquisitions", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments, acquisitions", "label": "Short-term Investments, Acquisitions", "documentation": "The increase in current investment resulting from origination or purchase." } } }, "auth_ref": [] }, "inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ShortTermInvestmentsAndNonCurrentFinancialAssets", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, total", "periodEndLabel": "Ending balance, total", "label": "Short-term Investments And Non-current Financial Assets", "documentation": "The amount of short-term investments and non-current financial assets." } } }, "auth_ref": [] }, "inpha_ShortTermInvestmentsForeignCurrencyEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ShortTermInvestmentsForeignCurrencyEffect", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": "inpha_TotalForeignCurrencyEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments, foreign currency effect", "label": "Short-term Investments, Foreign Currency Effect", "documentation": "The increase (decrease) in current financial assets resulting from foreign exchange and other movements." } } }, "auth_ref": [] }, "inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": "inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails", "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments, variation of fair value through the consolidated statement of income (loss)", "label": "Short-term Investments, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)", "documentation": "The gains (losses) on current financial assets at fair value through profit or loss." } } }, "auth_ref": [] }, "ifrs-full_ShorttermEmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermEmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails", "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Personnel expenses other than share-based compensation", "terseLabel": "Personnel expenses other than share-based compensation", "label": "Short-term employee benefits expense" } } }, "auth_ref": [ "r293" ] }, "inpha_SignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareDilutedincomelosspershareDetails", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [line items]", "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareDilutedincomelosspershareDetails", "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r197" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementScenarioAxis", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [] }, "inpha_StockOptions20201Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "StockOptions20201Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options 2020-1", "label": "Stock Options 2020-1 [Member]", "documentation": "Stock Options 2020-1" } } }, "auth_ref": [] }, "inpha_StockOptions20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "StockOptions20241Member", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options 2024-1", "label": "Stock Options 2024-1 [Member]", "documentation": "Stock Options 2024-1" } } }, "auth_ref": [] }, "inpha_StrategicPartnershipWithSwedishOrphanBiovitrumABMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "StrategicPartnershipWithSwedishOrphanBiovitrumABMember", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic partnership with Swedish Orphan Biovitrum AB", "label": "Strategic Partnership With Swedish Orphan Biovitrum AB [Member]", "documentation": "Strategic Partnership With Swedish Orphan Biovitrum AB" } } }, "auth_ref": [] }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "lang": { "en-us": { "role": { "label": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "auth_ref": [] }, "inpha_SubcontractingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SubcontractingCosts", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Subcontracting costs", "label": "Subcontracting Costs", "documentation": "The amount of subcontracting costs." } } }, "auth_ref": [] }, "inpha_SummaryOfChangesInWorkingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "SummaryOfChangesInWorkingCapitalAbstract", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in working capital", "label": "Summary Of Changes In Working Capital [Abstract]", "documentation": "Summary Of Changes In Working Capital" } } }, "auth_ref": [] }, "inpha_TaxAmortizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TaxAmortizationMember", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets / Tax amortization", "label": "Tax Amortization [Member]", "documentation": "Tax Amortization" } } }, "auth_ref": [] }, "inpha_TaxCreditRetentions2023CIR": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TaxCreditRetentions2023CIR", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Retentions 2023, CIR", "label": "Tax Credit Retentions 2023, CIR", "documentation": "Tax Credit Retentions 2023, CIR" } } }, "auth_ref": [] }, "inpha_TaxCreditRetentions2024CIR": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TaxCreditRetentions2024CIR", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Retentions 2024, CIR", "label": "Tax Credit Retentions 2024, CIR", "documentation": "Tax Credit Retentions 2024, CIR" } } }, "auth_ref": [] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]", "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6", "r146" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [domain]", "label": "Temporary difference, unused tax losses and unused tax credits [domain]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r6", "r146" ] }, "inpha_The2016FreePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "The2016FreePreferredSharesMember", "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The 2016 free preferred shares", "label": "The 2016 Free Preferred Shares [Member]", "documentation": "Related to the 2016 free preferred shares." } } }, "auth_ref": [] }, "inpha_The2017FreePreferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "The2017FreePreferredSharesMember", "presentation": [ "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The 2017 free preferred shares", "label": "The 2017 Free Preferred Shares [Member]", "documentation": "Related to the 2017 free preferred shares." } } }, "auth_ref": [] }, "inpha_TotalAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TotalAcquisitions", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total, acquisitions", "label": "Total, Acquisitions", "documentation": "The increase in short-term investments and non-current financial assets resulting from origination or purchase." } } }, "auth_ref": [] }, "inpha_TotalCashCashEquivalentsAndFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TotalCashCashEquivalentsAndFinancialAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails", "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, cash equivalents and financial assets", "terseLabel": "Cash, cash equivalents and financial assets", "label": "Total Cash, Cash Equivalents And Financial Assets", "documentation": "The amount of cash, cash equivalents and financial assets." } } }, "auth_ref": [] }, "inpha_TotalForeignCurrencyEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TotalForeignCurrencyEffect", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total, foreign currency effect", "label": "Total, Foreign Currency Effect", "documentation": "The increase (decrease) in short-term and non-current financial assets resulting from foreign exchange and other movements." } } }, "auth_ref": [] }, "inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract", "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Total Short-Term Investments And Non-Current Financial Assets [Abstract]", "documentation": "Total Short-Term Investments And Non-Current Financial Assets" } } }, "auth_ref": [] }, "inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total, variation of fair value through the consolidated statement of income (loss)", "label": "Total, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)", "documentation": "The gains (losses) on short-term investment and non-current financial assets at fair value through profit or loss." } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 }, "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and others", "totalLabel": "Payables and others", "label": "Trade and other current payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r203" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/TradepayablesandothersDetails": { "parentTag": "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/TradepayablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Suppliers (excluding payables related to capital expenditures)", "label": "Current trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r268", "r299" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others", "totalLabel": "Receivables and others - current", "label": "Trade and other current receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r188", "r201", "r213" ] }, "ifrs-full_TradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayables", "crdr": "credit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "inpha_ChangeInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade payables and others (excluding payables related to capital expenditures)", "label": "Trade and other payables" } }, "en": { "role": { "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]" } } }, "auth_ref": [ "r203" ] }, "ifrs-full_TradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/TradereceivablesandothersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Trade receivables and others", "label": "Trade and other receivables" } }, "en": { "role": { "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]" } } }, "auth_ref": [ "r188", "r201", "r213" ] }, "inpha_TradeAndOtherReceivablesExcludingReceivablesRelatedToPropertyEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TradeAndOtherReceivablesExcludingReceivablesRelatedToPropertyEquipment", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": { "parentTag": "inpha_ChangeInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others - current and non-current portion (excluding receivables related to Property & equipment)", "label": "Trade And Other Receivables, Excluding Receivables Related To Property & Equipment", "documentation": "Trade And Other Receivables, Excluding Receivables Related To Property & Equipment" } } }, "auth_ref": [] }, "inpha_TradePayablesAndOthersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TradePayablesAndOthersMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and others", "label": "Trade Payables And Others [Member]", "documentation": "This member stands for trade payables and others." } } }, "auth_ref": [] }, "inpha_TradeReceivablesAndOthersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TradeReceivablesAndOthersMember", "presentation": [ "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables and others", "label": "Trade Receivables And Others [Member]", "documentation": "This member stands for trade receivables and others." } } }, "auth_ref": [] }, "inpha_TransferFromToCollaborationCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TransferFromToCollaborationCurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer from / (to) collaboration liabilities", "label": "Transfer From / (To) Collaboration Current Liabilities", "documentation": "Transfer From / (To) Collaboration Current Liabilities" } } }, "auth_ref": [] }, "inpha_TransferFromToCollaborationLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TransferFromToCollaborationLiabilities", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer from / (to) collaboration liabilities", "label": "Transfer From (To) Collaboration Liabilities", "documentation": "The decrease in contract liabilities resulting from transfer to collaboration liabilities." } } }, "auth_ref": [] }, "inpha_TransferToFromCollaborationLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TransferToFromCollaborationLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer from / (to) collaboration liabilities", "label": "Transfer To (From) Collaboration Liabilities", "documentation": "The decrease in contract liabilities resulting from transfer to collaboration liabilities." } } }, "auth_ref": [] }, "inpha_TransferToFromCollaborationNonCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TransferToFromCollaborationNonCurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer from / (to) collaboration liabilities", "label": "Transfer To (From) Collaboration Non Current Liabilities", "documentation": "Transfer To (From) Collaboration Non Current Liabilities" } } }, "auth_ref": [] }, "ifrs-full_TravelExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TravelExpense", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Travel expenses and meeting attendance", "label": "Travel expense" } } }, "auth_ref": [ "r293" ] }, "ifrs-full_TreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasurySharesMember", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareDilutedincomelosspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares", "label": "Treasury shares [member]" } }, "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r197" ] }, "inpha_TypeOfEmployeeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TypeOfEmployeeAxis", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type Of Employee [Axis]", "label": "Type Of Employee [Axis]", "documentation": "Type Of Employee" } } }, "auth_ref": [] }, "inpha_TypeOfEmployeeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "TypeOfEmployeeDomain", "presentation": [ "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type Of Employee [Domain]", "label": "Type Of Employee [Domain]", "documentation": "Type Of Employee [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TypesOfContractsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsAxis", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails", "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts [axis]", "label": "Types of contracts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r248", "r250", "r261" ] }, "ifrs-full_TypesOfContractsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsDomain", "presentation": [ "http://www.innate-pharma.com/role/CommitmentsDetails", "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails", "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails", "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts [domain]", "label": "Types of contracts [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } } }, "auth_ref": [ "r248", "r250", "r261" ] }, "ifrs-full_TypesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfFinancialAssetsAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of financial assets [axis]", "label": "Types of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r105", "r106" ] }, "ifrs-full_TypesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfFinancialAssetsDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails", "http://www.innate-pharma.com/role/TradereceivablesandothersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of financial assets", "label": "Types of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated types of financial assets. It also represents the standard value for the 'Types of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r105", "r106" ] }, "ifrs-full_TypesOfInterestRatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInterestRatesAxis", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of interest rates [axis]", "label": "Types of interest rates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r287" ] }, "ifrs-full_TypesOfInterestRatesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInterestRatesDomain", "presentation": [ "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of interest rates", "label": "Types of interest rates [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r287" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [axis]", "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r84", "r167" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [domain]", "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r84", "r167" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets / Tax losses carry forwards - US", "label": "UNITED STATES" } } }, "auth_ref": [] }, "inpha_UnrealizedLossesOnFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "UnrealizedLossesOnFinancialAssets", "crdr": "debit", "calculation": { "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized losses on financial assets", "label": "Unrealized Losses On Financial Assets", "documentation": "The amount of unrealized losses on financial assets." } } }, "auth_ref": [] }, "ifrs-full_UnusedTaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedTaxLossesMember", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseDisclosureofDeferredAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets / Tax losses carryforwards", "label": "Unused tax losses [member]" } }, "en": { "role": { "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r6", "r146" ] }, "inpha_UnusedTaxLossesSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "UnusedTaxLossesSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused tax losses subject to expiration", "label": "Unused Tax Losses Subject To Expiration", "documentation": "The amount of unused tax losses subject to expiration." } } }, "auth_ref": [] }, "inpha_UnusedTaxLossesWithNoExpirationDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "UnusedTaxLossesWithNoExpirationDate", "crdr": "debit", "presentation": [ "http://www.innate-pharma.com/role/IncometaxexpenseAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused tax losses with no expiration date", "label": "Unused Tax Losses With No Expiration Date", "documentation": "The amount of unused tax losses with no expiration date." } } }, "auth_ref": [] }, "inpha_UpfrontPaymentCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "UpfrontPaymentCommitment", "crdr": "credit", "presentation": [ "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDetails", "http://www.innate-pharma.com/role/EventsafterthereportingdateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment, commitment", "label": "Upfront Payment Commitment", "documentation": "Upfront Payment Commitment" } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r280" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share)", "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r286" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails", "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares, basic (in shares)", "verboseLabel": "Weighted average number of ordinary shares in circulation (in shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r30" ] }, "inpha_WithholdingRateCIR": { "xbrltype": "percentItemType", "nsuri": "http://www.innate-pharma.com/20260630", "localname": "WithholdingRateCIR", "presentation": [ "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Withholding rate CIR", "label": "Withholding Rate, CIR", "documentation": "Withholding Rate, CIR" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_a&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_f&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "86", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86_a&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_a&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B51&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "105", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_105_a&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "180", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_180_b&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "204", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_a&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_c&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230_b&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "259", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259_a&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "259", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "43", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_a&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_b&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_c&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "72", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_a&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_vi&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2026-01-01", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.49", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_l&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_b&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_b&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_b&doctype=Standard", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "87", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_87&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Section": "Example 10 A court case", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex10_TI", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B33&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_d&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "193", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_a&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_144&doctype=Standard", "URIDate": "2025-03-27" }, "r277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "57", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard", "URIDate": "2025-03-27" }, "r288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }